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These STIKO vaccination recommendations were endorsed during the 79th and 81st 
STIKO meetings and are considered enacted upon their publication on 24 August 2015. 
This 2015 version replaces the previous STIKO vaccination recommendations published in 
August 2014 in Epidemiologisches Bulletin (Epid. Bull.) 34/2014 of the Robert Koch Institute 
(RKI). The scientific rationale for the modified STIKO recommendations will be available 
in Epid. Bull. 35/2015, 36/2015, and 37/2015 on the RKI website (www.stiko.de/en).
Preliminary remarks
Vaccinations are among the most effective and significant preventive medical 
measures. Modern vaccines are well tolerated, and serious long-term adverse 
events are observed only in very rare cases. The immediate goal of vaccination 
is to protect an individual from a specific disease. Given a high level of accep-
tance within the population and a consistent vaccination policy supported by all 
stakeholders, high vaccination coverage rates can be attained. Consequently, it 
is possible to achieve regional elimination of single pathogens, and eventually 
to eradicate them worldwide. Elimination of measles, rubella, and poliomyelitis 
are specified and achievable goals of national and international health policy.
Compulsory vaccination does not exist in Germany. Vaccinations and other 
means of specific prophylaxis are “publicly recommended” by the health authorities 
of the Länder (federal states) and are based on STIKO recommendations according 
to § 20 (3) of the Protection Against Infection Act [Infektionsschutzgesetz (IfSG)]. 
Compensation in case of vaccination-induced injury caused by publicly recom-
mended vaccinations is assured by the federal states.
An important task for a physician is to ensure adequate immunisation for all 
persons under his care. This means starting primary immunisation early in 
infants and toddlers, administering these vaccines without delays, and 
completing vaccination schedules in a timely manner. Following primary 
immunisation, using regular booster vaccinations when applicable, the physician 
must insure that the necessary protection is maintained throughout the life of the 
individual, and that immunisation against further infectious diseases is initiated 
when indicated. Therefore, every visit to the physician should be used to check the 
vaccination records of children, adolescents, and adults and, when appropriate, to 
complete immunisation schedules.
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Disclaimer
This document is a translation of the original Recommendations of the Standing Committee on 
Vaccination (STIKO) at the Robert Koch Institute (http://www.rki.de/stiko-empfehlungen) on 
behalf of the Robert Koch Institute as of 8/2015. The German text is authoritative, and no liability is 
assumed for any translation errors or for the translation’s correctness in case of subsequent revisions 
to the German original.
Overview of new or updated recom- 
    mendations in 2015
 ▶ Routine pneumococcal vaccination 
in infants and toddlers using the 
2+1 scheme (see immunisation 
schedule p. 329 and p. 339)
 ▶ Meningococcal serogroup B vacci-
nation for persons at increased risk 
(see table 2, p. 334 and p. 338)
 ▶ Modification of the recommenda-
tion for yellow fever vaccination 
(see table 2, p. 331 and p. 340)
 ▶ Revision of the recommendation 
for passive immunisation with 
varicella-zoster-immunoglobulin 
(see table 3, p. 347)
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The routine immunisation schedule for infants, children, 
adolescents and adults (Table 1) includes vaccinations against 
tetanus (T), diphtheria (D/d), pertussis (aP/ap), Haemophilus 
influenzae type b (Hib), poliomyelitis (IPV), hepatitis B (HB), 
pneumococci, rotavirus (RV), meningococcal C, measles, 
mumps, rubella (MMR), varicella, HPV and influenza. The 
recommended time of vaccination is indicated in weeks, 
months, and years. For example, “vaccination at the age of 
5 to 6 years” means that vaccination should occur between 
the day of the child’s 5th birthday and the day before the 7th 
birthday. Vaccination should occur at the earliest recom-
mended time. To keep the number of injections as low as 
possible, combination vaccines should preferably be used. It 
is recommended to check and, when necessary, update the 
vaccination status at every age. Missing vaccinations should 
immediately be administered in accordance with the recom-
mendations for the respective age. Regarding minimum 
intervals between two vaccinations and the possibility of 
co-administering vaccines, the Summary of Product 
Characteristics (“physician insert”) for the respective 
vaccine should be consulted. It is of particular importance 
for long-term vaccine-induced protection that, for primary 
immunisation, the recommended minimum interval between 
the second-to-last and last vaccination (usually 6 months) is 
not shortened. The specified vaccination intervals take 
into account the minimum intervals between vaccinations 
necessary to induce protection. 
Vaccination cards should be checked and subsequent 
immunisations provided when indicated during the 
healthy-child visits that infants and children under-
go, the school-entry health examination, health checks 
that take place throughout schooling, adolescent health 
checks, examinations in accordance with the Young 
Persons Employment Act [Jugendarbeitsschutzgesetz], 
and preventive medical examinations for adults. All 
persons with chronic diseases should receive the standard 
vaccinations recommended in the immunisation schedule as 
long as there are no specific contraindications.
Because of the particular threats faced in early childhood, 
the goal must be to administer recommended vaccinations 
for infants as early as possible and to complete primary 
immunisations by the recommended ages of 14 and 23 
months at the latest. Experience shows that vaccinations 
started later than recommended are often not continued 
within the correct timeframe. Until vaccination gaps have 
been detected and closed, for instance at the school-entry 
health examination, inadequately vaccinated children have 
insufficient vaccination protection. Age-appropriate full 
vaccination protection must be ensured before entry to a 
community facility, at the latest prior to starting school. 
In adolescents, missed vaccinations must be reinstated by 
the age of 18 at the latest (that is, by the day before their 
18th birthday).
Please note that catch-up vaccination against Hib should be 
administered only until the age of 5 years and vaccination 
against pneumococci only until the age of 2 years. Rotavi-
rus vaccination must be completed by the ages of either 24 
or 32 weeks depending of the brand of vaccine used.
Immunisation plan (routine vaccinations)
In addition to administering the vaccine, the vaccination services provided by the physician include:
 ▶ Providing information on the disease to be prevented and the benefits of vaccination;
 ▶ Providing information on possible adverse events following immunisation;
 ▶ Taking the patient’s medical and vaccination history, including possible existing contraindications;
 ▶ Determining current health status in order to exclude acute illnesses;
 ▶ Giving behavioural recommendations subsequent to the vaccination;
 ▶ Giving information on the commencement and duration of the protective effect;
 ▶ Giving advice on booster vaccinations; and
 ▶ Documenting the vaccination in the patient’s vaccination card or issuing a vaccination certificate.
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Standard vaccinations for adults; indicated and booster vaccinations, and vaccinations for  
increased occupational risk or travel
In addition to vaccinations recommended by STIKO, 
further “vaccination indications” are possible based on 
the existing market authorisation for a vaccine. These 
are not discussed further below, but they can be useful 
for an individual, depending on his or her individual 
health situation. It is the physician’s responsibility to 
inform patients of these additional protective options. 
Therefore, the lack of a STIKO recommendation 
should not prevent a physician from carrying out 
further vaccinations when justified.
To comply with the immunisation schedule for infants, 
children, adolescents and adults (see Table 1, p. 329) vaccina-
tion status should be checked regularly and brought up to 
date where necessary; each medical consultation should 
be utilised for this.
Beside standard vaccinations (S), other vaccinations may 
be indicated in a particular epidemiological situation or 
where there is a particular hazard to children, adolescents, 
and adults; these are referred to as indicated vaccinations (I). 
Vaccinations due to occupational risks (O) and travel vac-
cinations (T) are particular cases of indicated vaccinations 
and are therefore also listed. Travel vaccinations may be 
required to comply with international health regulations 
(including yellow fever vaccination) or may be recommen-
ded for individual protection while travelling.
It is the physician’s responsibility to recommend the type 
and chronological order of vaccinations in each individual 
case, considering the indications and, where applicable, 
existing contraindications.
If the individual indication for vaccination is not covered 
by a market authorisation valid for Germany or by the 
Summary of Product Characteristics for the corresponding 
vaccine, it comprises an off-label use. In case of injury, 
off-label use has consequences for liability and compen-
sation and places particular obligations on the physician 
administering the vaccine regarding documentation and 
the provision of information. Benefit claims for injury due 
to vaccination pursuant to § 60 Infektionsschutzgesetz 
(IfSG) are granted only for vaccinations officially recom-
mended by state health authorities.
The vaccinations mentioned in Table 2 differ both in terms 
of their epidemiological significance and in terms of the 
coverage of their cost (see notes on the cost coverage of 
protective vaccines, p. 343); they are divided into the 
following categories:
S Standard vaccinations for general application  
 (see also Table 1, p. 329, immunisation plan)  
B Booster vaccinations
I Indicated vaccinations for risk groups with a personally  
 (rather than professionally) increased risk of exposure,  
 illness, or complications, as well as to protect third   
 parties
O  Vaccinations due to an increased occupational/pro-
fessional risk, for example after risk assessment in 
accordance with the Occupational Safety and Health 
Act [Arbeitsschutzgesetz], the Biological Agents Ordi-
nance [Biostoffverordnung, the Regulation Concerning 
Occupational Healthcare [Verordnung zur arbeitsme-
dizinischen Vorsorge (ArbMedVV)], and the ‘G 42’ 
screening, as well as for hygiene reasons
T  Travel vaccinations
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Vaccination Cate- Indication Notes on use 
against gory  (Note package leaflet/Summary of Product Characteristics)
Cholera Periods of residence in infected areas, especially with inadequate 
hygiene conditions in current outbreaks, e. g., in refugee camps 
or during natural disasters.
According to the Summary of Product Characteristics.T
Diphtheria S/B All persons with absent or incomplete primary immunisation, 
or if either the last vaccination for the basic immunisation or 
the last booster vaccination occurred greater than 10 years 
previously.
Adults should receive the next due diphtheria vaccination 
as a one-time Tdap combination vaccination, if indicated 
as a Tdap-IPV combination vaccination.
If diphtheria vaccination is indicated and adequate 
vaccination protection against tetanus and pertussis 
is in place, a monovalent diphtheria vaccine should 
be given.
Unvaccinated persons or those with no vaccination re-
cord should receive 2 vaccinations at intervals of 4 – 8 
weeks and a 3rd vaccination 6 – 12 months after the 2nd 
vaccination.
Travel to an epidemic area should not be undertaken 







Persons exposed to ticks in TBE risk areas.
Persons at risk of TBE through their profession (exposed 
laboratory personnel as well as those in risk areas, including 
forest workers and those exposed during farming).
Note seasonality: April – November
Particular risk areas in Germany are currently:
 ▶ Baden-Württemberg
 ▶ Bavaria (with the exception of most of Swabia and the 
western part of Upper Bavaria)
 ▶ Hesse (district of Odenwald, district of Bergstraße, district 
of Darmstadt-Dieburg, city district of Darmstadt, district of 
Groß-Gerau, district of Offenbach, city district of Offenbach, 
distirct of Main-Kinzig-Kreis, district of Marburg-Biedenkopf)
 ▶ Rhineland-Palatinate (district of Birkenfeld)
 ▶ Saarland (district of Saar-Pfalz)
 ▶ Saxony (district of Vogtlandkreis)
 ▶ Thuringia (city district of Jena, city district of Gera, district 
of Saale-Holzland-Kreis, district of Saale-Orla-Kreis, district 
of Saalfeld-Rudolstadt, district of Hildburghausen, district of 
Sonneberg, district of Greiz)
Tick exposure in TBE risk areas outside Germany.
Primary immunisation and booster vaccinations with a 
vaccine authorised for adults and/or children according 
to the Summary of Product Characteristics.
According to the recommendations of the health au-
thorities, information on TBE risk areas must be noted; 
these are published in Epid. Bull. 21/2015. 
Yellow fever R  ▶ Before staying in known endemic regions in Africa and Latin 
America; please consult publications of the World Health 
Organization (WHO) with information on yellow fever 
endemic areas 
or
 ▶ according to the vaccination requirements of the destination 
or transit countries*
One-time vaccination in yellow fever immunisation 
facilities approved by health authorities.
*Since the implementation of the current changes in 
the International Health Regulations (IHR), which state 
that a single dose of yellow fever vaccine is sufficient to 
confer life-long protective immunity and a booster dose 
every 10 years is no longer necessary, will take until July 
2016, information on countries requiring yellow fever 
vaccination for entry (eg WHO: http://www.who.int/
entity/ith/2015-ith-county-list.pdf?ua=1//; 
http://www.who.int/entity/ith/2015-ith-annex1.pdf?ua=1) 
should be considered until then (Web link contains a list 
of countries with the yellow fever vaccine requirements 
and the further need of a yellow fever booster dose).
Table 2: Standard vaccinations for adults; indicated, and booster vaccinations
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 ▶ Persons whose sexual behaviour entails a high risk of infection.
 ▶ Persons frequently receiving blood components, e. g., 
haemophiliacs, or persons with liver diseases/diseases 
involving the liver.
 ▶ Residents of psychiatric institutions or comparable welfare 
facilities for people with behavioural disorders or cerebral 
damage.
 ▶ Health care workers (including kitchen, laboratory, technical 
and cleaning services, ambulance services, psychiatric and 
welfare institutions, sheltered employment facilities, and 
asylum seekers’ shelters), including trainees and students: at 
risk of contact to potentially infectious stools.
 ▶ Sewer system and wastewater workers in contact with sewage.
 ▶ Employment (including kitchen and cleaning) in children’s 
day care centres, children’s homes, and the like. 
Those travelling in regions with a high prevalence of hepatitis A.
Primary immunisation and booster vaccination accor-
ding to the Summary of Product Characteristics.
Serological screening for anti-HAV is required only for 
persons who have lived for prolonged periods in ende-
mic regions or grew up in families from endemic regi-






 1. Persons who are at risk of severe hepatitis B owing to an 
existing or expected immunodeficiency or immunosuppres-
sion, or owing to other pre-existing diseases, for example: 
HIV-positive individuals, hepatitis C-positive individuals, and 
patients on haemodialysis.a 
 2. Persons who are at increased risk of non-occupational 
exposure, for example: persons in contact with HBsAG 
carriers in the family or flat share, persons at high risk to 
acquire hepatitis B through sexual contact, injection 
drug users, prison inmates, and if applicable psychiatric 
inpatients.a 
 3. Persons who are at increased risk of occupational exposu-
re, for example: Health care personnel at risk of exposure 
(including trainees, laboratory personnel, and cleaning per-
sonnel), first aid providers, police officers, and personnel at 
facilities where an increased prevalence of hepatitis B-virus 
(HBV)-infected persons is likely to be present (for example, 
correctional facilities, shelters for asylum seekers, and ho-
mes for the handicapped).a,b
 4. Travel-related indication: an individual risk assessment is re-
quired. 
a This list of groups of persons provides examples and is not intended 
to be a definitive list of indicated groups. In any case, an individual risk 
assessment is required (see Epid. Bull. 36/2013).2
b In the field of occupational health services, the recommendations of the 
ArbMedVV should be attended as well.
c For persons belonging to indication group 4 (travel vaccination) it is 
necessary to evaluate whether, in view of the real risk of exposure and the 
individual risk of non-responding, serological monitoring is necessary.
For indication groups 1 – 4, the following applies:
Routine serological testing to rule out an existing HBV 
infection prior to hepatitis B vaccination is not neces-
sary. It is riskless to vaccinate persons already infected 
with HBV against hepatitis B; however, the vaccination 
is not effective. Serological testing can be reasonable in 
specific situations (for example, for financial reasons, 
to avoid unnecessary vaccinations, or in case of high 
anamnestic risk of exposure, including if a sexual part-
ner is HBsAG positive).b
To monitor vaccination success, anti-HBs level should 
be determined 4 – 8 weeks after the 3rd vaccine dose 
(successful vaccination: anti-HBs ≥ 100 IU/l).c 
For “low-responders” (anti-HBs 10 – 99 IU/l) an imme-
diate additional vaccine dose is recommended in con-
nection with repeated anti-HBs monitoring 4 – 8 weeks 
after vaccination. If anti-HBs is still < 100 IU/l, up to 
2 additional doses are recommended with subsequent 
anti-HBs monitoring 4 – 8 weeks after each vaccination. 
There is controversy over reasonable proceedings if the 
anti-HBs level remains < 100 IU/l after the administra-
tion of in total 6 vaccine doses; for further explanation 
see Epid. Bull. 36/2013.2
In the case of “non-responders” (anti-HBs < 10 IU/l) 
it is recommended to test for HBsAG and anti-HBc 
to exclude an existing chronic HBV infection. If both 
parameters are negative, proceed as described for 
“low-responders,” above.
After successful primary vaccination, defined as anti-
HBs ≥ 100 IU/l, routine booster immunisations are 
usually not necessary. The exceptions are patients with 
humoral immune deficiency (annual anti-HBs moni-
toring and a booster dose when anti-HBs < 100 UI/l), 
and if applicable, persons who are at particularly high 
individual exposure risk (anti-HBs monitoring after 10 
years and a booster dose if anti-HBs < 100 UI/l).
An additional vaccine dose followed by serological mo-
nitoring described above should be administered to per-
sons vaccinated against hepatitis B during infancy with a 
newly arisen risk for hepatitis B infection (see indications 





I Persons with anatomical or functional asplenia. One-time vaccination. Whether revaccination is useful 
can currently not be assessed because of insufficient 
data.
Yellow fever O  ▶ when working with contact to Yellow Fever Virus (eg in 
research institutions or research laboratories)
One-time vaccination in yellow fever immunisation 
facilities approved by health authorities.
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Adults ≥ 60 years of age.
All pregnant women from the second trimester, or from the first 
trimester in case of an increased health risk resulting from an 
underlying disease.
Children, adolescents and adults with an increased health risk 
resulting from an underlying disease, such as:
 ▶ Chronic diseases of the respiratory tract (including asthma 
and COPD;)
 ▶ Chronic cardiovascular, liver and kidney diseases
 ▶ Diabetes and other metabolic diseases
 ▶ Chronic neurological diseases, e. g., multiple sclerosis with 
relapses triggered by infections
 ▶ Persons with congenital or acquired immunodeficiencies with 
residual T- and/or B-cell function
 ▶ HIV infection
 ▶ Residents of nursing homes.
Persons at increased risk, e. g., medical personnel, persons in 
establishments dealing extensively with the public, as well as 
persons who may be possible sources of infection by caring for 
individuals at particular risk.
Persons at increased risk by direct contact with poultry and wild 
birds.
For travellers aged > 60 years and the groups of persons named 
under I (indicated vaccination) whose influenza vaccination sta-
tus is not up to date, vaccination is generally advisable. For other 
travellers an influenza vaccination may be advisable after a risk 
assessment depending on exposure and vaccine availability.
If a full-scale epidemic based on experiences in other countries 
is impending or is to be expected following a manifest antigenic 
drift or antigenic shift and the vaccine contains the new variant.
Yearly vaccination in autumn with a vaccine containing 
the current antigen combination recommended by 
WHO.
Vaccination with a vaccine containing the current anti-
gen combination recommended by the WHO.
Annual vaccination in autumn with a vaccine contai-
ning the current antigen combination recommended 
by the WHO. 
Children and adolescents aged 2 to 17 years can be vac-
cinated with an inactivated influenza vaccine or a live 
attenuated influenza vaccine (LAIV) if no contraindica-
tions exist (see Summary of Product Characteristics). 
LAIV should be preferred in children aged 2 to 6 years.
Yearly vaccination in autumn with a vaccine containing 
the current antigen combination recommended by 
WHO. 
Vaccination with the current seasonal human influenza 
vaccine does not offer direct protection against infection 
with the avian influenza virus. It can, however, prevent 
double-infection with the currently circulating influenza 
viruses (see also: TRBA 608 of the ABAS at www.baua.de 
> Topics from A – Z > Biological Agents > Technical Rules 
for Biological Agents).
Vaccination with a vaccine containing the current anti-
gen combination recommended by the WHO.









Those ≥ 18 years and born after 1970 with unclear vaccination 
status, who have not been vaccinated, or who received only one 
vaccination during childhood.
With forthcoming admission or visit of a community facility (e. g. 
Kindergarten): 
 ▶ infants from the age of 9 months
During an outbreak:
 ▶ Those born after 1970 from the age of 9 months with unclear 
vaccination status, who are unvaccinated, or who received 
only one vaccination during childhood.
 ▶ 6 to 8 month-old infants exceptionally after individual risk be-
nefit consideration (Off-label-use) 
One-time vaccination, preferably with a MMR vaccine.
Vaccination with 2 doses of a MMR/V*-vaccine
Provided that the first vaccination has been given at 
the age of 9 to 10 months, the 2nd MMR/V-vaccination 
should be given at the beginning of the 2nd year of life. 
One-time vaccination with MMR(V)**-vaccine
If necessary complement vaccinations according to 
the recommendations applying for the respective age 
group. Provided that the first vaccination has been 
given at the age of 9 to 10 months, the 2nd MMR/V 
vaccination should be given at the beginning of the 2nd 
year of life.
(Table 2 continued)
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Those whose health is at risk: Persons with congenital or acquired 
immunodeficiencies with residual T- and/or B-cell function, espe-
cially: 
 ▶ complement/properdin deficiencies, 
 ▶ Treatment with Eculizumab (monoclonalal antibody against 
terminal complement component C5)
 ▶ hypogammaglobulinaemia
 ▶ asplenia.
During outbreaks or regional clusters upon recommendation by 
the local health authorities (see p. 348).
At-risk laboratory personnel (in the case of work involving a risk 
of N. meningitidis aerosols).
Those travelling to countries with epidemic/hyperendemic oc-
currences, especially in close contact with the indigenous popu-
lation (e. g., development aid workers, disaster relief workers, 
medical personnel, long-term stays); this also applies to stays 
in regions with disease outbreaks and vaccination recommen-
dation for the indigenous population (note WHO and country-
specific information).
Before a pilgrimage (Hajj, Umrah).
Students before long-term stays in countries with recommended 
standard vaccination of adolescents or selective vaccination of 
students.
Vaccination against serogroups A, C, W, Y and/or B, if li-
censed for the respective age group.
For further details regarding implementation of meningo-
coccal vaccination see p. 338
In accordance with the recommendations of the health 
authorities.
Vaccination with quadrivalent ACWY-conjugate vaccine 
and a Men-B-vaccine. 
Vaccination with a quadrivalent conjugate vaccine, if li-
censed for the respective age group (see p. 339).
Vaccination with a quadrivalent conjugate vaccine 
(serogroups A, C, W, Y), if licensed for the respective 
age group (see p. 339). Take note of entry regulations.
One-time vaccination with MMR vaccine.
Mumps O Individuals born after 1970 with unclear vaccination status, who 
have not been vaccinated, or who received only one vaccination 
in childhood and who are working in health care with direct pati-
ent contact, in community facilities, or in educational establish-
ments for young adults.15




Adults should receive the next due Td vaccine as a one-time Tdap 
combination vaccine.
If in the last 10 years there has been no pertussis vaccination, the 
following groups should receive one dose of pertussis vaccine:
 ▶ women of childbearing age;
 ▶ persons in close household contact (parents and siblings) 
and caregivers (e. g., day nannies, babysitters, and where ap-
plicable grandparents), if possible 4 weeks before the birth 
of the child.
If a mother was not vaccinated before conception, she should 
preferably be vaccinated during the first days following the birth 
of her child.
If in the last 10 years there has been no pertussis vaccinati-
on, personnel in health care as well as in community facilities 
should receive one dose of pertussis vaccine.
Vaccination with a Tdap combination vaccine, if indica-
ted as a Tdap-IPV combination vaccine. (For available 
vaccines, please see Table 8, p. 359.)
(Table 2 continued)
Measles I
O Those born after 1970 with unclear vaccination status, who have 
not been vaccinated, or who received only one vaccination du-
ring childhood and who are working in health care or commu-
nity facilities, or who care for immunodeficient or immunosup-
pressed individuals.
With first vaccination at the age of 6 to 8 months a 2nd 
and 3rd MMR/V*-vaccination should be administered at 
the age of 11 to 14 and 15 to 23 months
* MMR/V = MMRV or MMR in co-administration with VZV 
vaccine
** MMR(V) = MMR with or without co-administration of VZV 
vaccine
One-time vaccination with a MMR vaccine.
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Adults ≥ 60 years of age.
Children, adolescents and adults at increased health risk as a 
result of an underlying disease:
1. Congenital or acquired immunodeficiencies or immunosup-
pression, such as:
 ▶ T-cell deficiency or defective T-cell function
 ▶ B-cell or antibody deficiency (e. g., hypogammaglobulinaemia)
 ▶ Deficiency or dysfunction of myeloid cells (e. g., neutropenia, 
chronic granulomatosis, leukocyte adhesion deficiencies, sig-
nal transduction defects)
 ▶ Complement and properdin deficiencies
 ▶ Functional hyposplenism (e. g., sickle cell anaemia), splenec-
tomy*, or anatomical asplenia
 ▶ Neoplastic diseases
 ▶ HIV infection
 ▶ After bone marrow transplantation
 ▶ Immunosuppressive therapy* (e. g., due to organ transplanta-
tion or autoimmune disease)
2.  Chronic diseases, such as:
 ▶ Chronic diseases of the cardiovascular system, respiratory tract 
(e. g., asthma, emphysema, or COPD), liver, or kidney
 ▶ Metabolic diseases, e. g., diabetes mellitus
 ▶ Neurological diseases, e. g., cerebral palsy or seizure disorders
3. Anatomical and foreign-material associated risks for pneumo-
coccal meningitis, such as:
 ▶ Cerebral spine fluid fistula
 ▶ Cochlea implant*
*vaccination preferably before intervention
One-time vaccination with a polysaccharide vaccine.
At-risk infants ≤ 4 years should receive a vaccination with 
the pneumococcal conjugate vaccine (the requisite num-
ber of doses depends on age – please see Table 7, p. 353); 
see the STIKO statement concerning indicated vaccina-
tions of children at risk in Epid. Bull. 33/2010.
From the age of 5 years, the 13-valent pneumococcal con-
jugate vaccine or the 23-valent polysaccharide vaccine 
can be used for vaccination.
For the following indications the administration of one 
vaccination or, if necessary, several repeat vaccinations at 
intervals of 5 years (adults) or at minimum 3 years (child-
ren under 10 years of age) can be considered:
1. Congenital or acquired immunodeficiencies, including 
    functional or anatomical asplenia (indication group 1, 
     left column)
2. Chronic kidney diseases/nephrotic syndrome
See the STIKO statement concerning pneumococcal vac-
cination with conjugate or polysaccharide vaccine for 
adults in Epid. Bull. 7/2012, p. 55 – 56.
Poliomyelitis S/B
I
All persons with no or incomplete primary immunisation.
All persons without a one-time booster vaccination.
A vaccination is indicated for the following groups of persons:
 ▶ Those travelling in regions with risk of infection (the current 
epidemic situation must be taken into account, especially the 
WHO reports)
 ▶ Immigrants, refugees and asylum seekers who live in com-
munal accommodation, entering from regions at risk of polio; 
see p. 344
Adults are considered fully immunised if they have recei-
ved the complete primary immunisation in infancy and 
childhood and at least one booster vaccination in adole-
scence or later, or if they have received primary immunisa-
tion as adults in accordance with the Summary of Product 
Characteristics and have received a booster vaccination.
Missing primary immunisation vaccinations are reinstated 
with IPV in accordance with the Summary of Product Cha-
racteristics.
Beyond the above, a routine booster vaccination is not re-
commended for adults. 
Vaccination or booster vaccination with IPV, if primary 
immunisation is incomplete or not fully documented or 
the last vaccination dates back longer than 10 years.
Persons with no primary immunisation record should re-
ceive at least 2 doses of IPV before starting their travels.
(Table 2 continued)
O  ▶ Personnel of the above-mentioned institutions
 ▶ Medical personnel who may have close contact with cases
 ▶ Personnel in laboratories with a poliomyelitis risk.
Vaccination or booster vaccination with IPV, if primary 
immunisation is incomplete or if the last of the primary 
or the last booster vaccination dates back longer than 
10 years.
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Vaccination Cate- Indication Notes on use 
against gory  (Note package leaflet/Summary of Product Characteristics)
Rubella I
O
Women of childbearing age that are non-immunised or with an 
unclear vaccination status. 24
Women of childbearing age vaccinated once. 24
Non-vaccinated persons or persons with an unclear vaccination 
status in paediatrics, obstetrics and pregnancy care institutions 
as well as in community facilities.
Two vaccinations with MMR vaccine.
One vaccination with MMR vaccine.





 ▶ Veterinarians, hunters, forest workers and other persons who 
handle animals in areas where there is a new occurrence of 
rabies among wild animals
 ▶ Persons with professional or other close contact with bats
 ▶ Laboratory personnel at risk of exposure to rabies viruses.
Those travelling in high risk rabies regions (e. g., from stray 
dogs).
Vaccination with the currently available BCG vaccine is not re-
commended.
Dosage schedule according to the Summary of Product 
Characteristics.
Persons with a continued exposure risk should regular-
ly receive a booster vaccination according to the Sum-
mary of Product Characteristics.
Laboratory personnel working with the rabies virus 
should be examined every 6 months for neutralising 
antibodies. A booster vaccination is indicated at < 0.5 
IU/ml serum.
Typhus T When travelling in endemic regions. According to the Summary of Product Characteristics. 
Varicella I
O
 ▶ Seronegative women who wish to conceive
 ▶ Seronegative patients prior to planned immunosuppressive 
therapy or organ transplantation
 ▶ Susceptible patients with severe neurodermatitis
 ▶ Susceptible persons in close contact with the two previously 
mentioned groups
Seronegative personnel in health care, especially in the fields of 
paediatrics, oncology, obstetrics and gynaecology, intensive care 
medicine, those involved in the care of immunodeficient per-
sons, and new workers in community facilities for preschool-age 
children.
According to the Summary of Product Characteristics.
For information on the vaccination of seronegative 
patients receiving immunosuppressive therapy, please 
refer to Epid. Bull. 39/2005. 
“Susceptible persons” are defined as individuals with 
no vaccination and no history of varicella or no specific 
antibodies detected upon serological testing.
Tetanus S/B All persons with no or incomplete primary immunisation, if the 
last primary immunisation vaccination or the last booster vacci-
nation dates back longer than 10 years.  
Adults should receive the next due tetanus vaccination 
as a one-time Tdap combination vaccination, if indica-
ted as a Tdap-IPV combination vaccination.
Incomplete primary immunisation should be completed, 
booster vaccination should occur at 10-year intervals.
(Table 2 continued)
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Diphtheria
From the age of 5 or 6 years, a vaccine with reduced diph-
theria toxoid content (d) is used for booster vaccination and 
for primary immunisation, generally combined with tetanus 
toxoid and pertussis antigen or other indicated antigens.
Haemophilus influenzae type b (Hib) 
From 5 years of age, Hib vaccination is indicated only in 
exceptional cases (see Table 2, p. 332), for example functional 
or anatomical asplenia. 
Hepatitis B (HB)
Pre- and post-vaccination serological testing is not ne-
cessary to monitor the success of primary immunisa- 
tion in childhood and adolescence. Revaccination 10 years 
following vaccination of infants and toddlers is currently 
not generally recommended for children and adolescents. 
Individuals who have been vaccinated against hepatitis B 
during childhood should be revaccinated against hepatitis 
B if a new risk for hepatitis B has evolved (for example, new 
employment in health care). A serological test should be 
conducted 4 – 8 weeks after vaccination according to re-
commendations in Table 2 (see p. 332) as well as Epid. Bull. 
31/20073 and 36/20132.
Post-exposure Hepatitis B prophylaxis in newborns of 
HBsAg positive mothers or of mothers of unknown HBsAg 
status
According to the maternity guidelines, all pregnant 
women should have their serum analysed for HBsAg 
after the 32nd week of pregnancy and as close as possible to 
the due date. If the result is positive, immunisation of the 
newborn against hepatitis B must begin immediately 
postpartum, that is, within 12 hours. The first dose of HB 
vaccine and HB immunoglobulin are thereby simultaneously 
administered. Primary HB immunisation thus started should 
be completed with a 2nd vaccination 1 month after the 1st 
vaccination, and with a 3rd vaccination 5 months at the earliest 
after the 2nd vaccination.
In newborns including premature babies of mothers 
whose HBsAg status is not known and in whom serological 
testing is not possible before or immediately after delivery, 
primary immunisation with the HB vaccine should also be 
started immediately postpartum regardless of birth weight. 
If the mother is later determined to be HBsAg positive, 
passive immunisation subsequently can be performed in 
the newborn child within 7 days after birth.
Serological testing is required after the completion of 
primary immunisation in the newborn child of an HBsAg 
positive mother: 4 – 8 weeks after the 3rd vaccination dose, 
HBsAg, anti-HBs, and anti-HBc are to be checked.  
Because a lower birth weight can cause a reduced antibody 
response, in infants of less than 1,000 gr a serological test 
(anti-HBs) should be conducted 4 weeks after the 2nd vac-
cination. If the anti-HBs level is ≥ 100 IE/l, the 3rd vacci-
nation is given 5 months after the 2nd vaccination. If the 
anti-HBs level is < 100 IE/l, the 3rd vaccination should be 
administered immediately. Another anti-HBs serological 
test should be conducted 4 weeks later in those infants. 
If levels are ≥ 100 IE/l, a 4th vaccination should be given 
9  months after the last immunisation. If no immunity 
exists after the 3rd vaccination, the 4th dose is to be admi-
nistered immediately. Vaccination success is checked by se-
rological testing (see above). Further measures (including 
possible 5th and 6th vaccinations) need to be decided on an 
individual basis (see Epid. Bull. 10/2000 and 8/2001).  
Human papilloma virus (HPV)
STIKO recommends routine vaccination against HPV 
(types 16 and 18) for all girls aged 9 to 14 years to redu-
ce the burden of disease due to cervical cancer. Missing 
HPV vaccinations should be completed before the age 
of 18 years (that is, the day before the 18th birthday). The 
vaccination series should be completed before first sexu-
al intercourse. Currently, a 2-dose scheme is licensed for 
children aged between 9 to 13 years (Gardasil®) or 9 to 
14 years (Cervarix®), with an administration interval of 
6 months between the 2 doses. A 3rd dose is necessary 
for catch-up vaccinations at the age of > 13 years and > 14 
years, respectively, or if the time intervals between the 1st 
and 2nd dose was < 6 months. Regarding the number of 
necessary vaccine doses as well as the required time inter-
vals between vaccinations, STIKO refers to the respective 
Summary of Product Characteristics.  
HPV vaccination should be utilised as an opportunity to 
bring other vaccinations for adolescents recommended 
by STIKO up to date. Concerning simultaneous adminis-
tration with other vaccines, STIKO refers to the respective 
Summary of Product Characteristics.
Women who are older than 17 years and have not received a 
HPV vaccination can also benefit from vaccination against 
HPV. It is within the physician’s responsibility to point this 
out to patients after an individual risk – benefit assessment 
based on the vaccine licensure.
Vaccinated persons must be informed that vaccination 
with one of the currently available vaccines against human 
papilloma viruses does not protect against all potentially 
oncogenic HPV types and that they must therefore still 
make use of cervical cancer screening services. A scientific 
evaluation of the changed HPV vaccination recommen-
dation, supplemental to the scientific rationale (Epid. Bull. 
12/2007)4 and the assessment of vaccination (Epid. Bull. 
32/2009)5, will be published in Epid. Bull. 36/2014.6
Notes on routine vaccinations listed in the immunisation plan
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Influenza
STIKO recommends annual vaccination in autumn with 
the current antigen combination recommended by the 
WHO as a standard vaccination for all persons aged 60 
years and older, and where indicated in specific groups of 
persons (see Table 2, p. 333). Annual vaccination is recom-
mended even when the antigen composition of the vacci-
ne is unchanged compared with the previous season.
Measles, Mumps, Rubella (MMR)
Vaccination against measles, mumps and rubella should 
be performed with a combination vaccine (MMR vacci-
ne), usually at the age of 11 to 14 months. The 2nd MMR 
vaccination should be completed by the age of 2 years to 
attain the earliest possible vaccination protection.
The 1st MMR vaccine dose can be administered from 
9 months of age depending on the epidemiological situati-
on, especially in the following situations:
 ▶ pending admission to a community facility (e. g. Kita)
 ▶ after contact with measles cases
There are no comprehensive data on the safety and effica-
cy of MMR vaccination in infants younger than 9 months. 
In the event of an outbreak, such infants must primarily be 
protected through immunisation of contact persons in their 
environment. Individual risk–benefit considerations can, in 
exceptional cases, justify vaccination at 6 to 8 months. In-
fants vaccinated between 6 to 8 months of age should receive 
2 additional doses of MMR vaccine at the age of 11 to 14 and 15 
to 23 months to establish long-term immunity.
Following the contact with measles cases, passive immu-
nisation with immunoglobulins can be considered up to 6 
days after exposition particularly for unprotected people with 
contraindicated vaccination and a high risk of complications, 
like infants less than 6 months of age, immunodeficient indi-
viduals and pregnant women. Infants between 6 to 8 months 
of age can receive immunoglobulins after individual risk- 
benefit consideration alternatively to the 1st vaccination. After 
administration of immunoglobulins, the MMR vaccination is 
not reliably effective for 5 – 6 months. This should be taken 
into consideration in the event of an indication for immuno-
globulin administration (see also Epid. Bull. 16/2013).
MMR vaccination is also recommended for all adults born 
after 1970 who have an unknown vaccination status, are 
unvaccinated, or have received only one vaccination in 
childhood, especially if they work in the health care or in 
community facilities, or if they care for immunodeficient 
or immunosuppressed individuals (one-time vaccination, 
preferably with an MMR vaccine). A background paper 
and detailed rationale for this recommendation can be 
found in Epid. Bull. 32/2010.11
Meningococcal B
A vaccine against serotype B meningococcal disease (Bexse-
ro®) was licensed in Europe in January 2013 and has been 
available in Germany since December 2013. STIKO currently 
concludes that the available study results and resulting evi-
dence are not sufficient for a conclusive decision regarding a 
universal vaccination recommendation. An updated STIKO 
comment regarding the status of the meningococcal B vac-
cine assessment will be published in Epid. Bull. 36/2014.23
However, STIKO recommends vaccination against serogroup 
B meningococci (MenB) in addition to MenACWY vaccinati-
on for persons with certain underlying diseases. (see Tab. 2, 
p. 334). Data regarding immunogenicity and efficacy of the 
MenB vaccine in these persons are lacking, but the immune 
response is likely to be weaker and of shorter duration than 
in healthy individuals. In addition, as detailed in the Back-
ground Paper “Update of meningococcal vaccination recom-
mendations in Germany: Use of the serogroup B vaccine in 
persons at increased risk for meningococcal disease“, the risk 
for IMD varies according to the underlying disease in questi-
on (See Bundesgesundheitsblatt. 2015; 58: 1314 – 43). Persons 
with terminal complement defects and properdin deficiency 
have by far the highest risk – up to 10,000-fold higher than 
background risk. IMD risk in persons with asplenia, on the 
other hand, is much lower, around 20- to 30-fold higher than 
background risk. The risk for persons with other immune 
defects, such as HIV infection or hypogammaglobulinemia 
is lower still. Thus the physician should base the decision for 
MenB vaccination on an individual risk assessment.
Meningococcal C
STIKO recommends the earliest possible vaccination 
against serogroup C meningococcal disease with a menin-
gococcal C conjugate vaccine for all children aged 12 to 23 
months. The primary goal of the vaccination is to reduce 
morbidity due to invasive serogroup C meningococcal di-
seases and sequelae such as hospitalisation, severe compli-
cations, disability and death.
In Germany, there is a subsequent and lower disease incidence 
peak in adolescents. A detailed justification for the vaccination 
recommendation can be found in Epid. Bull. 31/2006.14
Children aged up to 17 years with missing vaccinations 
should receive a catch-up vaccination. Concerning simulta-
neous administration with other vaccines, STIKO refers to 
the respective Summary of Product Characteristics.
In addition to this note, the recommendations on vaccina-
tion of persons at increased risk should be followed (see 
Table 2, p. 334).
Meningococcal ACWY
A meningococcal vaccination against serogroups ACWY is 
recommended for certain indications (see Table 2, p. 334 
and Table 3, p 346). In Europe, tetravalent MenACWY con-
jugate vaccines are licensed from the age of one (Nimen-
rix®) and 2 years (Menveo®), according to the Summary of 
Product Characteristics (July 1, 2015). In the US, Menveo® 
is licensed for children aged 2 months or older. For protec-
tion against MenC disease, MenC conjugate vaccines can 
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be administered from the age of 2 months onwards. The 
majority of IMD cases in infants are due to serogroup B 
(about 37 cases annually from 2010 to 2014), followed by 
serogroup C (6 cases annually), while only 0 to 2 cases an-
nually are due to serogroups A, W or Y. 
If protection against MenACWY is indicated after the first 
birthday following MenC vaccination in the first year of life, 
a tetravalent conjugate vaccine should be administered. 
Pertussis
Given the epidemiological pertussis situation in Germany 
and the severity of the clinical course of pertussis in infancy, 
it is advisable to start primary immunisation of infants and 
toddlers children at the earliest possible point in time, that 
is, immediately after 2 months of age, and to continue vacci-
nation in a timely manner. Booster vaccinations are recom-
mended at 5 – 6 years of age (see Epid. Bull. 3/2006) and 
9 – 17 years of age (see Epid. Bull. 17/2000). Vaccines with 
reduced pertussis antigen content (Tdap or Tdap-IPV) are 
used from 5 – 6 years of age both for booster vaccinations 
and, where applicable, for catch-up primary immunisations. 
STIKO recommends administering the next due Td vac-
cine for all adults as a one-time Tdap combination vacci-
nation or a Tdap-IPV combination vaccination if indica-
ted. Because a monovalent pertussis vaccine is no longer 
available, administration of combination vaccines is re-
commended on the respective vaccination dates. If there 
is an existing indication for pertussis vaccination, a Tdap 
combination vaccine can be used, even if a Td-containing 
vaccine has previously been administered. A placebo-con-
trolled study has demonstrated that one of the available 
Tdap combination vaccines can be administered within 1 
month after a previous Td vaccination without causing in-
creased side effects; see Epid. Bull. 33/2009, p. 340 – 341.
In the context of recognised pertussis clusters, vaccination 
can also be considered for fully vaccinated children and 
adolescents in close contact with cases in the household 
or in community facilities, if the last vaccination occurred 
longer than 5 years ago. Before the birth of a child, it is es-
pecially important that persons in close household contact 
with and carers of the newborn baby be checked for ade-
quate immunological protection against pertussis defined 
as vaccination within the past 10 years (see Table 2, p. 334). 
Pneumococcal
The primary goal of universal vaccination of all children up 
to 24 months of age with pneumococcal conjugate vaccine 
is to reduce morbidity from invasive pneumococcal disea-
ses (IPD) and sequelae such as hospitalisation, disability 
and death. Infants born at term should receive 3 vaccine 
doses at the ages of 2, 4, and 11 – 14 months (so-called 2+1 
scheme). The minimum interval between the 1st and 2nd 
dose is 2 months, and the minimum interval between the 
2nd and 3rd dose is 6 months. Preterm infants (born before 
37 completed weeks of gestation) should receive a total of 4 
vaccine doses at the ages of 2, 3, 4, and 11 – 14 months (3+1 
scheme). The deviant recommendation for preterm babi-
es is due to the licensure of the pneumococcal conjugate 
vaccines, which restricts the use of the 2+1 scheme to term 
infants so far (as of June 2015). A detailed justification of 
the pneumococcal vaccine recommendation can be found 
in Epid. Bull. 36/2015.
For persons ≥ 60 years of age, one-time vaccination 
against pneumococci with a pneumococcal polysaccharide 
vaccine is recommended as a standard vaccination. Repeat 
vaccinations at 5-year intervals should be performed only 
in certain indications (see Table 2, p. 335). The recommen-
dations for the vaccination of persons at increased risk are 
outlined in Table 2 (p. 335). If additional vaccination with 
pneumococcal conjugate vaccine is considered after vacci-
nation with pneumococcal polysaccharide vaccine, an in-
terval of at least 2 months between the respective vaccine 
doses should be adhered to according to the Summary of 
Product Characteristics.
A STIKO comment on the use of pneumococcal con-
jugate vaccine for adults can be found in Epid Bull. 7/2012.
Poliomyelitis
The oral polio vaccine (OPV) is no longer recommended 
owing to the risk – although very low – of vaccine-associa-
ted paralytic poliomyelitis. For protection against poliomy-
elitis, an injectable vaccine – inactivated polio vaccine (IPV) 
– is recommended. From 9 to 17 years of age, a booster vac-
cination containing IPV is recommended for adolescents. 
Primary immunisation started with OPV is to be completed 
with IPV. Additional information on vaccination against 
poliomyelitis is displayed in Table 2 (see p. 335).
Rotavirus (RV)
The RV vaccines are oral live vaccines. Depending on the 
used vaccine brand, 2 doses (Rotarix®) or 3 doses (Rota-
Teq®) are given to the infant starting at the age of 6 weeks, 
with at least 4 weeks between the vaccine doses. There is 
a possible slightly elevated risk for intussusception (esti-
mated at 1 – 2 cases per 100,000 infants vaccinated) within 
the 1st week after the 1st RV vaccine dose, which increases 
with age of the vaccinee. Therefore, STIKO strongly recom-
mends beginning the vaccination series as early as possib-
le – by the age of 12 weeks at the latest – and to complete 
it preferably by the age of 16 weeks (Rotarix®) or 20 – 22 
weeks (RotaTeq®). The vaccination series must be comple-
ted by the age of 24 weeks when using Rotarix® or at the 
age of 32 weeks when using RotaTeq®.
The background paper and detailed scientific rationale 
can be found in Epid. Bull. 35/2013.25 Concerning simulta-
neous administration with other vaccines, STIKO refers to 
the respective Summary of Product Characteristics.
RV-immunization is recommended for preterm infants 
at their chronological age and for full-term infants, even if 
hospitalized. The benefits of RV vaccination in neonatal 
intensive care units (NICU), providing protection against 
nosocomial RV-infection, significantly outweigh the low 
risk of RV gastroenteritis in other hospitalized patients 
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through nosocomial vaccine virus transmission. The risk 
of vaccine transmission is low and is sufficiently reduced 
by common infection control measures on NICUs. A joint 
statement of the STIKO, the German Academy for Pedi-
atrics and Adolescent Medicine (DAKJ) and the German 
Society for Neonatology and Pediatric Intensive Care Medici-
ne (GNPI) on RV-vaccination of preterm infants and neona-
tes during hospitalization is published in Epid. Bull. 1/2015.
Tetanus 
Each booster vaccination with Td (including in case of an 
injury) should be used as a reason to check whether pertus-
sis vaccination is indicated and, if applicable, to administer 
a combination vaccine (Tdap).
Tick-Borne Encephalitis (TBE)
TBE illnesses in children generally have a milder course than 
in adults, predominantly presenting symptoms of meningitis 
and more rarely symptoms of encephalitis. Residual neuro-
logical damage has been reported only in isolated cases. As 
febrile reactions of > 38°C have been observed in 15 % of 1- to 
2-year-old vaccinated children (as opposed to 5 % of 3- to 11-ye-
ar-old children), the recommendation is to carry out a par-
ticularly careful assessment of the indications together with 
the parents prior to vaccination of children under 3 years of 
age. Otherwise, the basic principles of indicated vaccination 
presented in Table 2, p. 331 apply to the paediatric vaccine and 
to the adult vaccine, including the information contained in 
the table on risk areas and on the seasonality of the disease.
Varicella
The 1st dose of the vaccination against varicella (V) is gene-
rally administered at age 11 to 14 months, either at the same 
time as the 1st MMR vaccination or, at the earliest, 4 weeks 
after it. For the 1st vaccine dose against varicella and MMR, 
the simultaneous application of a single varicella vaccine 
dose and an MMR combination vaccine at different body 
sites is preferable. The rationale for this recommendati-
on is a slightly increased risk of febrile seizures 5 – 12 days 
after application of the combined MMR-varicella (MMRV) 
vaccine compared with the simultaneous vaccination with 
a varicella and MMR vaccine. This increased risk was only 
observed after the 1st vaccination. The 2nd dose of varicel-
la vaccine should be administered between ages 15 to 23 
months and can be conducted with a MMRV combination 
vaccine; see the STIKO statement on “Combined vaccinati-
on against measles, mumps, rubella and varicella (MMRV)” 
in Epid. Bul. 38/2011.
In all non-vaccinated 9- to 17-year-old adolescents with no 
history of varicella, catch-up vaccination should also take 
place with two doses, in accordance with the Summary of 
Product Characteristics. The minimum interval between 
two doses of varicella or MMRV vaccine is 4 to 6 weeks (de-
pending on the Summary of Product Characteristics provi-
ded by the manufacturer). Children and adolescents who 
have only been vaccinated once against varicella should re-
ceive a second dose of varicella or MMRV vaccine.
The background paper and detailed scientific rationale for 
the varicella vaccination recommendation was published in 
Epid. Bull. 32/200927, and an evaluation of the recent vari-
cella vaccination strategy is found in Epid. Bull. 1/2013.
Yellow fever
Yellow fever vaccination is recommended when traveling 
to countries where yellow fever is endemic and is necessa-
ry in countries that require proof of yellow fever vaccina-
tion as a condition of entry. After reviewing the available 
evidence, World Health Organization (WHO) has declared 
in 2014 that a single dose of yellow fever vaccine provides 
lifelong protection. The current regulation that a certifi-
cate of yellow fever vaccination is valid for a period of 10 
years and a booster vaccination is necessary afterwards 
can be omitted. The change extending the validity of a 
certificate of vaccination against yellow fever from 10 years 
to lifelong will come into force from July 2016, so it may 
be possible that some countries still require a certificate 
not older than 10 years. Updates of current entry require-
ments can be found on the WHO web site: http://www.
who.int/entity/ith/2015-ith-county-list.pdf?ua=1//; http://
www.who.int/entity/ith/2015-ith-annex1.pdf?ua=1. 
Following persons may benefit from a booster dose because 
their immune response may be weakened and therefore a 
protection after a single vaccination will eventually not last 
lifelong: (1) children who were vaccinated for the first time 
at the age < 2 years, (2) women who have been vaccinated 
during pregnancy, (3) HIV-infected people, (4) individuals 
who get yellow fever vaccination and MMR vaccination 
simultaneously. 
The detailed scientific rationale for the adaption of the 
yellow fever vaccination recommendation can be found in 
Epid. Bull. 35/2015.
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Obligation for risk/benefit communication prior to 
immunisation 
Providing all relevant information is an important part of 
the vaccination service provided by the physician (see pre-
liminary remark, p. 327). Before carrying out an immuni-
sation, it is the physician’s duty to inform the person being 
vaccinated or their parent or guardian about the disease 
to be prevented and the vaccination; the aim is to enable 
them to make an informed decision about receiving the 
vaccination. The information should include: informati-
on on the disease to be prevented and the benefit of the 
vaccination, the contraindications, the administration of 
the vaccination, the onset and duration of vaccination pro-
tection, behaviour after the vaccination, possible adverse 
events following vaccination (see Epid. Bull. 25/2007), and 
the necessity of and timeframes for follow-up and booster 
vaccinations.
Providing written information is recommended 
during official vaccination appointments. The opportuni-
ty for further discussion with the physician must also be 
given. Information sheets for vaccinations by physicians 
are available on the website of the STIKO (www.rki.de > 
Infektionsschutz > Informationsmaterialien in verschiede-
nen Sprachen) and they are sold by commercial providers. 
In addition, information sheets are available free of charge 
on the home page of the “Forum for vaccinating physici-
ans” (www.forum-impfen.de) with a password.
The leaflets also contain a questionnaire appropriate to 
the respective vaccination on the state of health of the 
person being vaccinated and on previous immunisations. 
Should there be any uncertainty about the responses, a 
discussion with the person being vaccinated, or with their 
parents or guardians, is necessary in all cases. The leaf-
lets contain an informed consent form. For minors, the 
consent of the parents or guardians must routinely be 
obtained. Adolescents can give their own consent if they 
possess the required ability to reason and make a decisi-
on; this is usually the case at 16 years of age. For indivi-
dual vaccinations, verbal information is sufficient. A sig-
nature is also not required for consent. The information 
provided must be documented in the patient files by the 
physician administering the vaccine. If the information 
is based upon a relevant information sheet, the physician 
administering the vaccine should refer to this in his docu-
mentation. In this case, as well, the person being vaccina-
ted or the guardian must be given the opportunity to ask 
direct questions.
To support physicians in patient counselling, the cur-
rent STIKO vaccination schedule and informed consent 
forms for vaccination against measles, mumps, rubella 
and varicella have been translated into 15 different langu-
ages. These documents are published on the RKI website 
(www.rki.de/impfen).
Contraindications
Children, adolescents, and adults with acute diseases 
requiring treatment should only be vaccinated after recovery, 
with the exception of post-exposure vaccination.
Depending on the diagnosis, adverse events temporally cor-
related with a vaccination are not an absolute contraindi-
cation against a second vaccination with the same vaccine. 
Obstacles to vaccination can include allergies to components 
of the vaccine. Neomycin and streptomycin are important 
considerations, as well as egg protein in rare cases. Persons 
who react with anaphylactic symptoms after oral consump-
tion of egg protein should not be vaccinated with vaccines 
that contain egg protein (yellow fever and influenza vaccine).
In the case of congenital or acquired immunodeficiency, 
the physician treating the immunodeficiency should be 
consulted before vaccination with a live vaccine. Serological 
monitoring of the success of vaccination is indicated in pa-
tients with immunodeficiency. 
Vaccinations that are not urgently indicated should not be 
carried out during pregnancy. Live vaccines against meas-
les, mumps, rubella, and varicella are contraindicated in 
pregnancy. It is allowed to administer a yellow fever vac-
cination in pregnancy in case of clear indication and me-
rely after careful risk-benefit consideration. A yellow fever 
vaccination should not carried out in breastfeeding women. 
Worldwide there are reported sporadic cases of breastfed 
infants who came down with a meningoencephalitis after 
their mother had received a yellow fever vaccination.
False contraindications
Indicated vaccinations are often omitted because certain 
conditions are erroneously considered contraindications. 
These include:
 ▶ Commonplace infections, even if they are associated with 
subfebrile temperatures (< 38.5 °C);
 ▶ Possible contact of the person to be vaccinated with people 
with contagious diseases;
 ▶ Seizures in the family;
 ▶ Febrile convulsions in the medical history of the person to 
be vaccinated (as febrile vaccination reactions can provoke 
seizures, administering antipyretics to children who are 
prone to seizures should be considered, for example, in 
the case of inactivated vaccines, at the time of vaccination 
and again 4 and 8 hours after the vaccination, as well as 
between the 7th and 12th day following MMR vaccination 
in the case of a rise in temperature);
 ▶ Eczema including dermatoses and localised skin 
infections;
 ▶ Treatment with antibiotics or with low doses of corticos-
teroids or locally applied steroid-containing preparations;
General information on immunisations
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 ▶ Pregnancy of the mother of the person to be vaccinated 
(including varicella vaccination after risk assessment; 
see below*);
 ▶ Congenital or acquired immunodeficiencies upon vacci-
nation with inactivated vaccines;
 ▶ Neonatal jaundice;
 ▶ Premature birth: premature babies should be vaccinated 
according to the recommended vaccination age regardless 
of their age of maturity and current weight;
 ▶ Breastfeeding women: they can receive every required 
vaccination except a yellow fever vaccination (see above: 
Contraindications)
 ▶ Breastfed infants: they can be vaccinated according the 
specifications of the STIKO immunisation schedule 
independently of the kind of their feeding (breast milk, 
formula, or other kinds of baby food).
* Currently, the risk of connatal varicella syndrome in a seronegative pregnant 
woman in contact with her non-vaccinated child thus at risk of being infected 
is greater than the risk of such a complication through vaccination and, where 
applicable, transmission of vaccine-induced varicella via her child.
Indicated vaccinations should also be undertaken in persons 
with chronic diseases, as these persons are especially endan-
gered by severe courses and complications of vaccine-preven-
table diseases. Persons with chronic diseases should be edu-
cated on the benefits of vaccination compared with the risk of 
disease. There is no evidence that flare-ups or progressions 
of chronic diseases, which may occur in temporal association 
with vaccination, can be causally linked to vaccination.
Vaccination intervals
The vaccination intervals shown in Tables 1, 2, and 7 and 
in Summary of Product Characteristics sheets should ge-
nerally be complied with and neither be shortened nor 
prolonged. In the case of urgently indicated vaccinations, 
such as post-exposure rabies prophylaxis or postnatal im-
munoprophylaxis of hepatitis B in the newborn, the re-
commended vaccination schedule must be strictly adhered 
to. Minimum intervals should be shortened only in urgent 
exceptional cases (for example, a trip abroad at short noti-
ce). For long-lasting vaccination protection it is particularly 
important that, during the primary immunisation, the re-
commended minimum interval between the second-to-last 
and last vaccination (generally 6 months) is not shortened.
On the other hand, every vaccine dose counts! Additional 
vaccine doses are not required if intervals between already 
administered vaccine doses are longer than recommen-
ded. Even a primary immunisation that has been out of 
date for many years or a booster vaccination not carried 
out in a timely manner, for example against diphtheria, te-
tanus, poliomyelitis, hepatitis B, or TBE (see www.rki.de > 
Infektionsschutz > Impfen > Impfungen von A – Z > Ant-
worten auf häufig gestellte Fragen zur FSME-Impfung), 
does not have to be started again from the beginning, 
but is updated with the missing vaccine doses. This also 
applies to infants and toddlers children. In the interest 
of providing vaccination protection as early as possible, 
exceeding the recommended vaccination intervals should 
be avoided in young children.
The following applies to intervals between different 
vaccinations: 
 ▶ Live vaccines (attenuated, replication-competent viruses 
or bacteria) can be administered simultaneously. If they 
are not administered simultaneously, there must be a 
minimum interval of 4 weeks between the two vaccine 
administrations.
 ▶ In the case of immunisation with inactivated vaccines 
(inactivated pathogens, their antigen components, and 
toxoids) no minimum time interval between two vacci-
nations is necessary, even if one of the vaccines is a live 
attenuated vaccine. Possible adverse reactions following 
preceding vaccinations should have completely subsided 
prior to a new vaccination.
Interval between vaccinations and operations
If the indication is urgent, surgical procedures can be car-
ried out at any time, even if preceded by a vaccination. In 
the case of elective procedures, a minimum interval of 
3 days should be allowed after the administration of 
inactivated vaccines and a minimum interval of 14 days 
after the administration of live vaccines.
Neither clinical observations nor theoretical considera-
tions suggest that vaccinations and surgical procedures are 
incompatible. However, to distinguish between possible 
vaccination reactions and surgical complications, it is re-
commended that these minimum intervals between vacci-
nations and operations be maintained. With the exception 
of vital vaccinations (such as tetanus, rabies, and hepatitis 
B vaccination), these minimum intervals also apply to vac-
cination following major surgical procedures. Following 
operations associated with immunosuppressive treatment, 
e. g., transplantations, vaccinations must be planned in 
cooperation with the attending physician.
Handling of vaccines and procedure during vaccination
Vaccines are sensitive biological products that must be 
especially protected from a rise in temperature. Vaccines 
containing replication-competent viruses are particularly 
sensitive. All vaccines should be stored in the refrigerator at 
2 – 8°C. The storage temperature must be checked regularly. 
Vaccines that, by mistake, were stored incorrectly or frozen 
must be discarded. Vaccines should not come into contact 
with disinfectants. The stoppers of injection vials must be dry!
The needle should be dry; in particular, the outside of the 
cannula should not become wet with vaccine. This causes 
the injection to be painful and can lead to inflammation in 
the region of the injection canal. After drawing the vaccine 
into the syringe and removing any air that might be present, 
a new needle should be fitted for the injection. The injection 
site must be disinfected prior to injection. The skin should 
be dry again at the time of injection.
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For vaccines injected via the intramuscular route, the pre-
ferred injection site is the deltoid muscle. If this muscle is 
not sufficiently developed, injection into the vastus lateralis 
muscle (anterolateral thigh) is recommended. The risk of 
injury to nerves or vessels there is low. Injection of adsor-
bate vaccines into the subcutaneous fatty tissue can lead to 
painful inflammations and to the formation of granulomas 
or cysts. In addition, there is doubt about the success of 
vaccinations when injected into fatty tissue.
Documentation of the vaccination
The batch number, vaccine name (brand), date of vaccination 
and disease vaccinated against must be documented in the 
patient’s vaccination card and in the medical record of the 
physician administering the vaccine, in accordance with the 
specifications of the IfSG § 22. The stamp and signature of 
the physician are likewise part of the vaccination documen-
tation. This applies to all vaccines and can make retrospec-
tive investigation easier, should questions arise about the 
efficacy and safety of particular vaccines or individual vaccine 
batches. Any form that meets WHO requirements and that 
also makes allowance for the provisions of the IfSG, such as 
“International certificates of vaccinations and shot record”, 
can be used as a vaccination card.
Annex 2 of the immunisation guideline of the Federal Joint 
Committee (G-BA) designates a standard documentation 
code for vaccinations that has had to be used since 1 July 
2008 when billing statutory health insurance companies.
Missing vaccination documentation 
The physician is frequently confronted with missing, untra-
ceable or incomplete vaccination documents. This is not a 
reason for postponing necessary vaccinations, not catching 
up on missing vaccinations, or not starting primary immuni-
sation. No particular risk arises from additional vaccinations 
when vaccine-induced protection already exists. This also 
applies to multiple vaccinations with live virus vaccines. 
Serological tests to check the immune status of an individual 
are indicated only in exceptional cases (e. g., anti-HBs anti-
bodies for persons at increased risk of hepatitis B infection); 
serological tests to detect previous vaccinations in the case of 
unclear vaccination status are generally not useful.
Adverse events following vaccinations
Local reactions such as reddening, swelling and pain in 
the region of the injection site or general reactions such 
as fever (≤ 39.5°C), head and joint pain, and feeling un-
well, are generally observed within the first 72 hours fol-
lowing the vaccination. A mild “vaccination illness”, for 
example with symptoms resembling those of measles or 
mumps (immunisation measles; a slight swelling of the 
parotid glands) and elevated temperatures can occur 1 to 
4 weeks after MMR vaccination. Prophylactic administ-
ration of antipyretics may be considered for the period of 
potential febrile reactions to vaccination.
Severe adverse events following vaccinations are 
extremely rare. Illnesses with a different origin occurring 
at the same time as the vaccination can present as an 
adverse event; therefore an event exceeding the normal 
reaction to a vaccine must be subject to prompt differen-
tial diagnostic evaluation.
Procedure for adverse events following vaccination 
Suspicion of damage to health exceeding the usual scale 
of a reaction to vaccination must immediately be reported 
to the health authority (reporting obligation pursuant to 
§ 6 (1) no. 3 IfSG; request a report form from the health 
authority or via the internet at www.pei.de > Vigilanz > 
Übersicht Meldeformular). The Drug Commission of the 
German Medical Association must also be informed of ad-
verse drug reactions (via internet at www.akdae > Arznei-
mittelsicherheit > Unerwünschte Arzneimittelwirkung). 
The manufacturer can also be informed. The immunolo-
gical analysis (e. g., to exclude an immune deficiency) or 
microbiological analysis (e. g., for differential diagnostic 
exclusion of an intercurrent infection) relevant for diag-
nosing an adverse event following vaccination should be 
started without delay. Analysis material necessary for this, 
for example serum or stool samples, must be obtained. The 
vaccinated person or their parents or guardians must be infor-
med about the legal requirements concerning care following 
vaccination-induced injury (§ 60 – § 64 IfSG). The application 
for care must be made to the responsible healthcare office.
Information on cost coverage of immunisations
There are various possible payers for covering the cost of 
vaccinations. New regulations were established in 2007 
that define which vaccinations are covered by all statu- 
tory health insurance companies in Germany. According to 
§ 20 d of Book V of the Social Code [SGBV], insured per-
sons are entitled to vaccination pursuant to § 2 no. 9 of the 
Protection Against Infection Act (IfSG). Based on STIKO re-
commendations, the Federal Joint Committee (GBA) must 
determine, in a vaccination guideline (see www.g-ba.de), the 
details of the obligation to reimburse the cost of vaccinations 
(including requirements, type and scope). In doing so the 
particular significance of vaccinations for public health 
should be taken into account. Immunisations indicated 
owing to an increased health risk from a non-work-related 
stay abroad are excluded from this entitlement, unless, for 
the protection of public health, there is special interest in 
preventing the introduction of a transmissible disease into 
the Federal Republic of Germany (for example, travel vacci-
nations). If a GB-A decision is not made within 3 months 
following publication of the STIKO recommendations, tho-
se vaccinations recommended by STIKO must be provided 
by health insurance companies until the guideline comes 
into existence.
Health insurance companies can also include in their 
optional benefits coverage the reimbursement of the cost 
for further vaccinations that are not part of the guideline 
of the Federal Joint Committee. In addition, the health 
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insurance company associations have to jointly and 
uniformly make agreements regulating the funding of 
protective vaccinations and the reimbursement of vaccine 
costs at the regional level with the regional authorities res-
ponsible for carrying out vaccinations.
Apart from the health insurance companies, other payers 
are able to cover the cost of protective vaccinations. These 
include the Public Health Service [Öffentlicher Gesund-
heitsdienst (ÖGD)] for vaccinations pursuant to § 20 (5) of 
the IfSG, as well as other named entities based on legal re-
gulations (e. g., employers). For example, in accordance with 
§3 (3) of the Occupational Safety and Health Act [Arbeits-
schutzgesetz], an employer is not permitted to impose the 
costs of occupational safety measures on an employee. Oc-
cupational safety measures include vaccinations that must 
be offered in accordance with the Occupational Safety and 
Health Act [Arbeitsschutzgesetz]/Biological Agents Ordi-
nance [Biostoffverordnung]/Regulation Concerning Occu-
pational Healthcare [Verordnung zur arbeitsmedizinischen 
Vorsorge (ArbMedVV)]. The vaccinations offered are specifi-
cally determined by the outcome of a risk assessment.
The vaccinations denoted “O” in the STIKO recommenda-
tions also include those for professional groups that are not 
subject to the named ordinances. In this category, vaccina-
tions are also listed that are primarily indicated for the pro-
tection of third parties.
Even if the named regulations do not apply in these cases, it 
is in the interests of the employer concerned to offer these 
vaccinations, because in doing so the employer can counter 
possible claims for redress or save on the costs of down-
time among employees. How far the recommendations 
denoted “O” are standard services for the statutory health 
insurance companies is determined by the protective vac-
cination guidelines of the Federal Joint Committee. At 
present, this does not regularly provide for an entitlement 
to statutory health insurance company reimbursement 
in cases where the employer is responsible. However, for 
vaccinations recommended by STIKO that do not have to 
be covered by the employer, the statutory health insurance 
companies are obligated to reimburse the cost, based on 
the vaccination guideline.
Vaccination recommendations for immigrants, refugees, 
or asylum seekers in communal accommodation
It is recommended to begin immunising residents of com-
munal accommodation as soon as possible through the 
ÖGD or through physicians commissioned by the ÖGD. 
Primary immunisation should be completed by private 
physicians in the most recent place of residence or by the 
ÖGD after leaving communal accommodation.
Available vaccination documentation should, where possi-
ble, be taken into account; the procedure should be based 
on the STIKO recommendations.
 ▶ Unvaccinated adults and adults with unclear vaccinati-
on status should receive vaccinations against diphtheria 
and tetanus, against poliomyelitis and, in seronegative 
persons, against hepatitis B. Adults should receive the 
next due Td vaccination (booster vaccination) as a one-
time Tdap combination vaccination. Individuals born 
after 1970 should be vaccinated once against measles 
(MMR). Women of childbearing age should receive two 
vaccinations against rubella (MMR), and seronegative 
women who wish to conceive should be vaccinated twice 
against varicella.
 ▶ Unvaccinated children and children with unclear vacci-
nation status should receive vaccinations against diph-
theria, tetanus, and pertussis, as well as against polio-
myelitis, measles, mumps, rubella, varicella, hepatitis 
B, meningococcal C, and HPV (girls only); in addition, 
infants and toddlers should be vaccinated against rota-
virus, Haemophilus influenzae type b, and pneumococci.
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Information on post-exposure vaccinations and other measures of specific prophylaxis of 
communicable diseases
In addition to the recommendations for standard and indica-
ted vaccinations, STIKO issues recommendations regarding 
post-exposure vaccinations and other measures of specific pro-
phylaxis of contact persons in private and occupational settings 
and in community facilities. Those recommendations include 
advice on how insufficiently-protected individuals can be pro-
tected after exposure to specific infectious agents in order to 
prevent further spread of the disease or to mitigate the course of 
the disease. Post-exposure vaccination, passive immunisation by 
administration of immunoglobulins, and chemoprophylaxis are 
specified as preventive measures. Information on post-exposure 
prophylaxis of specific infectious diseases can also be found in 
the “RKI-Guidebook for physicians” (“Ratgeber für Ärzte” des 
RKI)(www.rki.de/ratgeber).
Diphtheria For persons in close (face to face) contact with cases. 
During epidemics or regionally increased morbidity.
Chemoprophylaxis: 
Independent of vaccination status, preventive anti-
biotic treatment is recommended, e. g., with Erythro-
mycin (see RKI-Guidebook for physicians “diphtheria”, 
www.rki.de > Infektionskrankheiten A – Z > Diphtherie). 
Post-exposure vaccination is indicated if the most 
recent vaccination occurred > 5 years previously.
In accordance with the recommendations of the health 
authorities.




Chemoprophylaxis is recommended after close contact with a 
patient with invasive Haemophilus influenzae type b Infection:
 ▶ For all household members starting at age 1 month, if either 
an unimmunised or insufficiently immunised child aged up 
to 4 years or a person with a relevant immunodeficiency is 
present;




From 1 month of age:   20 mg/kg/day (up to a maxi- 
  mum of 600 mg) in 1 single  
  dose for 4 days
Adults:    600 mg p. o. in 1 single dose for 4 days
As administration of rifampicin is contraindicated in 
pregnant women, ceftriaxone can be used for prophy-
laxis instead, if necessary.
If prophylaxis is indicated, it should be started as soon 
as possible, and at latest 7 days after the onset of 
disease in the index case
Hepatitis A
(HA)
Contact with hepatitis A patients (especially in community fa-
cilities).
Post-exposure vaccination:
Following exposure in persons for whom hepatitis A pre-
sents a particular danger (e. g., those chronically infec-
ted with HBV or HCV), an immunoglobulin preparation 
should be given simultaneously with the 1st vaccination. 
See also “Ratgeber Hepatitis A” [“Hepatitis A Guide“] at 
www.rki.de > Infektionskrankheiten A – Z > Hepatitis A.
Hepatitis B
(HB)
Injuries from objects potentially containing HBV (e. g., a needle 
stick) or blood contact with mucosa or non-intact skin.
Newborn babies either of HBsAg positive mothers or of mothers 
with unknown HBsAg status (regardless of birth weight).
See post-exposure hepatitis B immune prophylaxis, 
p. 348.
See comments on the vaccination schedule, p. 337.
Measles People with unclear vaccination status, who have not been 
vaccinated, or who received only one vaccination during child-
hood after contact with measles cases.
Vaccination with MMR(V)** vaccine preferably within 3 
days after exposition; according to the number of vacci-
ne doses or the time of administration please consider 
the following age-specific recommendations.
** MMR(V) = MMR with or without co-administration of 
VZV vaccine
Vaccine  Indication Notes on use
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Meningococcal Chemoprophylaxis is recommended for persons in close contact 




 ▶ All household contact members
 ▶ Persons in contact with a patient’s oropharyngeal secretions
 ▶ Contact persons in children’s establishments with children 
under 6 years of age (only in the affected group in cases whe-
re the groups are well separated)
 ▶ Persons in close contact in community facilities with a 
household-like character (for example, boarding schools, 
hostels and barracks)
Chemoprophylaxis is indicated if close contact with the index 
patient took place in the 7 days preceding the onset of illness. 
Chemoprophylaxis should take place as soon as possible after 
diagnosis of the index patient; however, it is useful up to 10 days 
after the last exposure.
In addition to chemoprophylaxis, meningococcal vaccinati-
on of unvaccinated household contacts or close contacts of a 
household-like character is recommended if the infection of the 
index case was caused by serogroups A, C, W Y or B. The vacci-
nation should be given as soon as possible after contact.13 
Chemoprophylaxis:
Rifampicin:
Newborn babies: 10 mg/kg/day in 2 single doses p. o.       
           for 2 days.
Infants, children and adolescents up to 60 kg:
20 mg/kg/day in 2 single doses p. o. for 2 days  
(maximum single dose 600 mg).
Adolescents and adults from 60 kg:
2 × 600 mg/day for 2 days.
Eradication rate: 72 – 90 %
Or:
Ciprofloxacin:
From 18 years of age: 1 × 500 mg p. o.
Eradication rate: 90 – 95 %
Where applicable, Ceftriaxone:
From 2 – 12 years of age: 125 mg i. m.
From 12 years of age: 250 mg i. m. in 1 single dose
Eradication rate: 97 %
Because administration of rifampicin and gyrase inhibi-
tors is contraindicated in pregnant women, ceftriaxone 
can be used as prophylaxis if necessary.
The index patient with an invasive meningococcal infec-
tion should also receive rifampicin after completion of 
therapy, unless he or she received intravenous treatment 
with a third-generation cephalosporin.
Vaccine  Indication Notes on use
(Table 3 continued)
Measles  ▶ at the age of 6 to 8 months: exceptionally after individual risk 
benefit consideration (Off-label-use)
 ▶ at the age of von 9 to 10 months
 ▶ at the age of 11 months to 17 years 
 ▶ at the age of 18 years or more, born after 1970
One-time vaccination; 
a 2nd and 3rd vaccination should be given at the age of 11 
to 14 and 15 to 23 months
One-time vaccination;
the 2nd vaccination should be given at the beginning of 
the 2nd year of life.
People with unclear vaccination status or who have not 
been vaccinated vaccination with 2 doses administered 
at least 4 weeks apart; People who have received only 
one vaccination receive 1 more vaccination.
People who have not been vaccinated, with unclear vac-
cination status, or who have been given only one vac-
cination during childhood receive 1 more vaccination. 
Passive immunisation with immunoglobulins can be 
considered up to 6 days after exposition particularly for 
unprotected people with contraindicated vaccination 
and a high risk of complications, like infants less than 6 
months of age, immunodeficient individuals and preg-
nant women where necessary.
Infants between 6 to 8 months of age can receive im-
munoglobulins after individual risk-benefit considerati-
on alternatively to the 1st vaccination. 
After administration of immunoglobulins, the MMR 
vaccination is not reliably effective for 5 – 6 months. 
This should be taken into consideration in the event of 
an indication for immunoglobulin administration (see 
also Epid. Bull. 29/2001, S. 223).
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Tetanus See Table 5, p. 350.
Rabies See Table 6, p. 351.
Varicella 1. In non-immunised persons with no history of varicella and in 
contact with persons at increased risk.
2. Persons at increased risk of varicella complications, 
including:
 ▶ Non-immunised pregnant women with no history of 
varicella
 ▶ Immunocompromised patients with uncertain or absent 
varicella immunity
 ▶ Newborn babies whose mothers became ill with varicella 
between 5 days preceding and 2 days following delivery.
 ▶ Preterm-babies born in or after the 28th gestation week, 
whose mothers are not immune, if exposed in the neo-
natal period
 ▶ Preterm babies born before the 28th gestation week if ex-
posed in the neonatal period regardless of their mother’s 
immune status
Post-exposure vaccination within 5 days of exposure* or 
within 3 days following commencement of the rash in 
the index case. Independent of these measures, contact 
with persons at risk (for example, those listed in point 2) 
should be avoided at all costs
Post-exposure administration of varicella zoster immu-
noglobulin (VZIG) as soon as possible within 3 to 10 
days at maximum following exposure*. VZIG can prevent 
or markedly alleviate the outbreak of disease.
Please follow the Summary of Product Characteristics 
for the administration and dosing of VZIG!
Post-exposure prophylaxis with VZIG might be accom-
plished by use of antivirals.
* Exposure is defined as:
 ▶ 1 hour or longer with an infectious person in a room
 ▶ Face to face contact
 ▶ Household contact
Mumps Non-immunised persons, persons immunised once during 
childhood, and persons with an unclear immune status in con-
tact with mumps cases, if possible within 3 days after exposure.
One-time vaccination with an MMR vaccine.
Pertussis Persons without vaccination protection in close contact in a 
family, shared accommodation, or a community facility.
Chemoprophylaxis with a macrolide is recommended 
(see also RKI-Ratgeber für Ärzte “Pertussis” [“Pertussis 
Guide“] at www.rki.de > Infektionskrankheiten A – Z > 
Pertussis).
Vaccine  Indication Notes on use
(Table 3 continued)
Poliomyelitis All contact persons of a poliomyelitis case regardless of their 
vaccination status. 
A secondary case is a cause for ring vaccinations.
Immediate post-exposure vaccination with IPV.
Immediate extensive investigations and stipulation of 
measures by the health authorities.
Ring vaccinations with IPV and stipulation of further 
measures by decree of health authorities.
Post-exposure vaccination:
 ▶ For serogroup C: 
Vaccination with a conjugate vaccine from 2 months 
of age, according to the Summary of Product 
Characteristics (see p. 338)
 ▶ For serogroups A, W or Y: 
Vaccination with a quadrivalent conjugate vaccine, 
if licensed for the respective age group (see p. 338)
 ▶ For serogroups B: 
Vaccination with a MenB-vaccine, according to the 
Summary of Product Characteristics and if licensed 
for the respective age group (p. 338)
See also updates in Epid. Bull. 33/2010 and Epid. Bull. 
31/2012.
Meningococcal
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Prompt prophylaxis is required in case of exposure to HBV. 
The following notes were compiled for application in the field 
of occupational health and can be transferred to other health 
service fields.
Lacerations and puncture wounds (especially with hollow 
needles) and blood contact with mucosa or broken skin pre-
sent a risk of infection. Any such event (for example, during 
patient care, the patient hereby called the “index patient”) 
should be reported as an occupational accident by the em-
ployee (hereby called the “exposed person”). The HBsAg 
status of the index patient and the HBV vaccination status 
of the exposed person should be determined.   
Further measures depend on the HBsAg status of the index 
patient:
1. If the index patient is HBsAg negative: further measures 
in regard to hepatitis B are superfluous.* If the exposed 
person is not vaccinated or vaccination is incomplete, 
primary immunisation should be started and completed, 
respectively.
2. If the index patient is HBsAg positive: further measures 
depend on the vaccination status of the exposed person 
and are explained below.
3. If the HBsAg status of the index patient is unknown: the 
HBsAg level of the index patient should be determined 
immediately (within 48 hours). Depending on the result 
of the HBsAg testing intervention should proceed as 
described in 1 or 2, above. If testing is not possible within 
48 hours or is simply not possible (e. g., injury due to a 
hollow needle in a trash bag), the index patient is classi-
fied as HBsAg positive, and further measures depend on 
the vaccination status of the exposed person (see #2). 
The proceedings described in the following are additionally 
depicted in a flow chart (see Figure 1).
For exposed persons with complete vaccination the  
following applies:
The measures to be taken depend on the most recent anti-
HBs level.
 ▶ Anti-HBs was determined within the last 10 years:
–  Anti-HBs was ≥ 100 IU/l: No action.
Post-exposure hepatitis B immunoprophylaxis after exposure to HBV-containing material
 ▶ A “meningococcal disease outbreak” is defined as two or 
more cases of the same serogroup within 4 weeks in a 
children’s facility, school class, playgroup, a community 
facility with a household-like character (for example, a 
hostel, boarding school, or barracks);
 ▶ A “regionally clustered occurrence” is defined as three or 
more cases of the same serogroup within 3 months
– in a restricted age group of the population (e. g., 
adolescents) in one place, or
– in a region with a resulting incidence ≥ 10/100,000 in 
the respective population.
As a supplement to antibiotic prophylaxis for close contact 
persons (see Table 3, p. 346, as well as the recommenda-
tions of the German Society of Paediatric Infectiology 
[Deutsche Gesellschaft für Pädiatrische Infektiologie 
(DGPI)], of the National Reference Centre for Meningococci, 
and the Ratgeber für Ärzte [Guide for Physicians] of the RKI), 
the responsible health authorities can additionally recom-
mend vaccination prophylaxis if the clustered occurrence or 
the outbreak was caused by a strain preventable by vaccina-
tion. Vaccination prophylaxis is justified by the possibility of 
further cases occurring up to a few months after the onset of 
the first illnesses.
As with antibiotic prophylaxis, close contacts in the 
households of patients, their intimate partners, and close 
contacts in children’s facilities, school classes, playgroups, 
and community facilities with a household-like character 
can be included in prophylactic vaccination in the event of 
an outbreak.
In the case of a regionally clustered occurrence, the decisi-
on of the responsible health authorities must be made con-
sidering the epidemiological and temporal correlations of 
the diseases, their age distribution, the level of public con-
cern, and the feasibility of the measures.
Authorised vaccines corresponding to the meningococcus 
serogroup causing the outbreak can be used for vaccination 
(see notes on use in Table 2, Meningococcal ACWY infec-
tions, category P, p. 334). 
Whenever meningococcal meningitis is suspected, material 
for isolation of the pathogen should immediately be sent to 
a suitable laboratory. The Public Health Department should 
urge that samples of isolated meningococci be dispatched 
as rapidly as possible to the National Reference Centre to 
ensure their detailed typing and to permit recommending 
preventive vaccination in the event of a clustered occurrence.
Vaccinations for clustered occurrences or outbreaks of meningococcal diseases
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*  Very rarely, HBs-Ag negative persons can be infectious. From a cost-benefit point of view, routine testing for HBV-DNA of all index patients is not practicable.
** An isolated positive result of an anti-HBc test necessitates further diagnostic clarification. However, required vaccination should not be delayed.
–  Anti-HBs was 10 – 99 IU/l: Immediate determination 
of the current anti-HBs level, with further action depen-
ding on the test result (see Table 4).
–  Anti-HBs was < 10 IU/l: Blood withdrawal (testing for 
HBsAg, anti-HBc, and anti-HBs), succeeded by immedi-
ate simultaneous administration of HB vaccine and HB 
immunoglobulin (without waiting for the test results).2 
Exception: If at a prior point in time, i. e. more than 10 
years ago, an anti-HBs ≥ 100 IU/l was recorded, only HB 
vaccine (not HB immunoglobulin) should be given (see 
the flow chart in Figure 1, p. 349).
 ▶ Last Anti-HBs testing was longer than 10 years ago or never 
(or if testing result is unknown): Immediate testing of the 
current anti-HBs level. Further action depends on the 
test result (see Table 4). 
For exposed persons with incomplete vaccination, the 
following applies:
 ▶ Immediate testing of the current anti-HBs level. Further 
action depends on the test result (see Table 4).
 ▶ Administration of missing vaccinations (where 
applicable, a shortened vaccination schedule can be 
used; see Summary of Product Characteristics). 
For unvaccinated exposed persons and known “non-respon-
ders” (individuals with permanent anti-HBs < 10 IU/l) the 
following applies:
 ▶ Blood withdrawal (testing for HBsAg, anti-HBc, anti-
HBs), and subsequent immediate simultaneous admi-
nistration of HB vaccine and HB immunoglobulin (wit-
hout waiting for the test results).** 
 ▶ For unvaccinated persons, two additional vaccine do-
ses (after the initial dose) should be given according to 
the standard vaccination schedule in order to achieve a 
complete primary immunisation. Antibody response fol-
lowing HB vaccination is not affected by simultaneous 










































than 10 years 




Anti-HBs was < 10 IU/l
Anti-HBs was 10 – 99 IU/l
Anti-HBs was ≥ 100 IU/l
No
No
Current anti-HBs ≥ 100 IU/l
Current anti-HBs 10 – 99 IU/l
* In incompletely vaccinated or unvaccinated persons vaccination schedule should be completed.
Current  
anti-HBs < 10 IU/l
or testing not possible 
within 48 h
Figure 1: Procedure for the hepatitis B immunoprophylaxis (see detailed information, p. 348)
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Previous history of tetanus immunisation Clean, negligible wounds All other wounds 1 
(# of tetanus vaccine doses received) DTaP/Tdap 2 TIG 3 DTaP/Tdap 2 TIG 3
Unknown Yes No Yes Yes
0 to 1 Yes No Yes Yes
2 Yes No Yes No 4 
3 or more No  5 No No 6 No
Post-exposure tetanus immunoprophylaxis in case of injury
Table 5: Tetanus immunoprophylaxis in case of injury
1  This includes wounds that are deep and/or soiled (contaminated with 
dust, earth, sputum, or stool), and injuries with tissue fragmentation 
and reduced oxygen supply or penetration of foreign bodies (e. g., con-
tused, lacerated, bite, puncture, or gunshot wounds). Further indica-
tions include:
 ▶ Severe burns and frostbite
 ▶ Tissue necrosis
 ▶ Septic miscarriages 
2  Children under 6 years old receive a combination vaccine with DTaP, 
while older children receive Tdap (that is, a tetanus and diphtheria vac-
cine with a reduced diphtheria toxoid content and reduced acellular 
pertussis component). Adults also receive Tdap if they have not yet 
received a Tdap vaccine as adults (≥ 18 years of age) or if there is a 
current indication for pertussis vaccination (see Table 2, p.334).
3  TIG = Tetanus immunoglobulin. Generally, 250 IU are administered but 
the dose can be increased to 500 IU; TIG is used simultaneously with a 
DTaP/Tdap vaccine.
4 Yes if the injury dates back longer than 24 hours.
5  Yes (1 dose), if more than 10 years have passed since the last vaccina-
tion.
6  Yes (1 dose), if more than 5 years have passed since the last vaccina-
tion.
Tetanus immunoprophylaxis must be carried out immedi-
ately. Missed primary immunisation vaccinations must be 
reinstated in accordance with the recommendations given 
for primary immunisation.
Current anti-HBs level Required administration of 
HB vaccine HB immunoglobulin
≥ 100 IU/l no no
10 – 99 IU/l yes no
< 10 IU/l, or not determinable 
within 48 hours  
and anti-HBs was ≥ 100 IE/l at a prior point in time yes no
and anti-HBs was never ≥ 100 IE/l, or is unknown yes yes
Table 4: Hepatitis B immunoprophylaxis after exposure depending on the current anti-HBs level  
              (see also flow chart, Figure 1)
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Notes on post-exposure rabies immunoprophylaxis:
 ▶ Potentially contaminated body sites and all wounds 
must be cleaned immediately and generously with soap 
or detergent, rinsed thoroughly with water, and treated 
with 70 % alcohol or an iodine preparation; this also 
applies to contamination with vaccination liquid from 
vaccine bait. When possible, wounds should not under-
go primary suturing.
 ▶ With exposure level II, a rabies vaccine is used for acti-
ve immunisation according to the Summary of Products 
Characteristics.
 ▶ With exposure level III, in addition to active immunisa-
tion, passive immunisation with rabies immunoglobulin 
is initiated. As much rabies immunoglobulin as possible 
is instilled in and around the wound, and the remaining 
amount is administered intramuscularly. 
 ▶ If an indicated administration of rabies immunoglobu-
lin was not administered at first vaccination, it can still 
be given until 7 days after the first dose of rabies vaccine.
 ▶ If a person who was previously vaccinated with rabies 
cell culture vaccines is newly exposed, the Summary of 
Product Characteristics must be followed.
 ▶ If the vaccination history shows either incomplete vacci-
nation or vaccination with vaccines not authorised in the 
EU, full immunoprophylaxis is carried out in accordance 
with Table 6.
 ▶ If indicated, immunoprophylaxis must be carried out 
immediately; there should be no delay while waiting for 
clarification of a suspected infection in the biting animal. 
If the suspicion of rabies in the animal is not confirmed 
by veterinary examination, immunoprophylaxis can be 
discontinued or continued as pre-exposure vaccination.
 ▶ Care must be taken to check tetanus vaccination docu-
mentation and if necessary to administer simultaneous 
tetanus immunoprophylaxis (see Table 5, p. 350).
Post-exposure rabies immunoprophylaxis







from a rabies vaccine bait
Touching of vaccine baits with intact skin.
Contact with the vaccination fluid of a damaged 
vaccine bait with broken skin.
Contamination of mucous membranes and 
fresh skin injuries with the vaccination fluid of a 
damaged vaccine bait.
Immunoprophylaxis*




Protective rabies vaccination and 
a single administration of rabies 
immunoglobulin (20 IU/kg body 
weight) simultaneously with the 
1st dose.
Type of exposure
from a wild animal, pet, or bat with suspected 
or confirmed rabies
Touching/feeding of animals;
licking of intact skin.
Superficial scratches or abrasions without blee-
ding; 
Licking or nibbling of broken skin.
Bites or scratches;
Sputum contact with mucous membranes or 
wounds (e. g., through licking);
Suspected bite or scratch from a bat or mucous 
membrane contact with a bat.
Table 6: Post-exposure rabies immunoprophylaxis
* Individual vaccinations and administration of rabies immunoglobulin must be carefully documented.
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Recommendations for catch-up vaccinations 
For children, adolescents and adults with incomplete or unknown vaccination status
Preliminary remarks
The present notes are based on the recommendations for 
routine vaccination of infants, children, adolescents and 
adults (Table 1, p. 329).
These notes are intended to guide physicians in deciding 
which vaccinations are required for unvaccinated, delayed, 
or incompletely vaccinated individuals to achieve the re-
commended vaccination protection according to age. Evi-
dence supporting this guidance is often limited, as studies 
of high methodological quality examining vaccine effective-
ness under irregular immunisation schedules are often not 
available. The recommendations given here are therefore 
mainly based on the long-term experience and expertise of 
STIKO members. In addition, expert opinions and the re-
commendations of other national and international immu-
nisation technical advisory groups were considered.1,2,8-13
Every physician consultation of children, adolescents and 
adults should be used to check the individual’s vaccination 
status and to prompt catch-up of missing vaccinations.
Unvaccinated persons and persons with unclear  
vaccination status
An overview regarding recommended catch-up vacci-
nations and the corresponding vaccination schedule for 
different age groups is given in Table 7. Age groups were 
chosen to incorporate age-related particularities in vacci-
nation recommendations and application notes according 
to the Summary of Product Characteristics of licensed 
vaccines. The relevant age is the age at start of the catch-up 
series.
Partly immunised persons
For partly immunised children, adolescents, and adults, all 
documented vaccinations up to the present are counted, if 
the interval between single doses was not shorter than the 
recommended minimum interval. For long-lasting vacci-
nation protection, it is especially important that the recom-
mended minimum interval between second-to-last and last 
vaccinations (6 months for most vaccines) is not shortened 
during primary immunisation (P). Given this prerequisite, 
the following applies:
Every vaccination counts!
This means that there are, in principle, no illegitimately long 
intervals between vaccinations. Usually, a primary immuni-
sation series that has been interrupted for many years – for 
example, against diphtheria, tetanus, poliomyelitis, or hepa-
titis B – does not have to be repeated. A booster vaccination 
that has not been administered according to schedule can 
also be administered at a later point in time.
In considering the number and timing of previously admi-
nistered vaccinations, an individual immunisation schedule 
should be compiled. The number of vaccine doses needed to 
complete the interrupted primary immunisation series is, in 
principle, calculated based on the recommendations for the 
age at which the vaccination series was started. For vaccina-
tions that are recommended only until a specific age, an in-
terrupted primary immunisation series will not be continu-
ed if the vaccinee has in the meantime surpassed this speci-
fic age.
Literature: see p. 360
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Table 7: Recommended catch-up vaccinations among children, adolescents and adults with missing  
             primary immunisation (P)
Children < 12 months
Vaccine Minimum interval in months after previous vaccination dose Age in years
0 1 1 6 5 – 8 9 – 17
Tetanus C1 C2 C3 C4 B1 B2
Diphtheria (D) C1 C2 C3 C4 B1 B2
Pertussis (aP) C1 C2 C3 C4 B1 B2
Hib C1 C2 a C3 C4
Poliomyelitis C1 C2 a C3 C4 B1
Hepatitis B C1 C2 a C3 C4
Pneumococcal C1 C2 C3
Unvaccinated persons: Apply the table using the patient’s current age
Partly immunised persons:  Apply table using the patient’s age when first vaccinated with the respective antigen
C = Catch-up vaccination  B = Booster vaccination P = Primary vaccination
Footnotes at the end of table 7
Children aged 12 months to < 5 years
Vaccine Minimum interval in months after previous vaccination dose Age in years
0 1 6 5 – 17
Tetanus C1 C2 C3 B1 b B2 b
Diphtheria (D) C1 C2 C3 B1 b B2 b
Pertussis (aP) C1 C2 C3 B1 b B2 b
Hib C1
Poliomyelitis C1 C2 C3 B1 c
Hepatitis B C1 C2 C3




MMR e C1 C2
Varicella e C1 C2
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Children from 5 to < 11 years
Vaccine Minimum interval in months after previous vaccination dose Age in years
0 1 6 10 – 17
Tetanus C1 C2 C3 B1 f
Diphtheria (d) C1 C2 C3 B1 f
Pertussis (ap) g C1 C2 C3 B1 f
Poliomyelitis C1 C2 C3 B1





Children/adolescents from 11 to < 18 years
Vaccine Minimum interval in months after previous vaccination dose Vaccination interval
0 1 6 5 – 10 years
Tetanus C1 C2 C3 B1
Diphtheria (d) C1 C2 C3 B1
Pertussis (ap) g C1 B1
Poliomyelitis C1 C2 C3 B1








9 – 14 P1 P2
> 14 C1 C2 C3
At the age of 9 – 13 years or 9 – 14 years (depending on product), HPV 
primary immunisation (P) consists of 2 doses 6 months apart. For 
catch-up vaccinations (C) and completion of vaccination series at age 
> 13 years and > 14 years, respectively, 3 doses are necessary (note  
Summary of Product Characteristics).
Footnotes at the end of table 7
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(Table 7 continued)
Adults over 18 years
Vaccine Minimum interval in months after previous vaccination dose Vaccination interval
0 1 6 every 10 years
Tetanus C1 C2 C3 B
Diphtheria (d) C1 C2 C3 B
Pertussis (ap) g C1 B1 (one-time)
Poliomyelitis C1 C2 C3 B1 (one-time)
Measles for persons 
born after 1970
C1
Rubella for women 
in childbearing age h
C1 C2
Varicella for serone-
gative women who 
wish to conceive 
C1 C2
According to the Recommendations of Routine Vaccinations (Effective: August 2015)
Hib = Haemophilus influenzae type b  MMR = Measles, mumps, rubella  HPV = Human papilloma virus
a) This dose can be omitted when using a monovalent vaccine.
b) Booster vaccination 5 – 10 years after the last dose of the primary immunisation, or after a previous booster vaccination.  
c) The booster vaccination should be administered at the age of 9 – 17 years.
d) The pneumococcal vaccination is not recommended as a routine vaccination after the age of 24 months; accordingly, there is no 
 need for catch-up vaccination.
e) Starting at the age of 11 months.
f) Depending on the age at completion of the primary immunisation, 2 booster vaccinations may be appropriate before adulthood; the 
 interval between P and B1 and between B1 and B2 is 5 – 10 years. 
g) As there is no monovalent pertussis vaccine available in Germany, only Tdap or Tdap-IPV combination vaccines can be used. 
h) Unvaccinated women or women without documented vaccinations are administered 2 doses, while one-time vaccinated women are 
 administered 1 dose. In absence of a monovalent rubella vaccine, an MMR vaccine can be used. 
A 2.5-year-old child received one dose each of the hexavalent vaccine 
DTaP-IPV-Hib-HepB and the pneumococcal vaccine at 2 and 3 months; 
after this point, no further vaccinations were given.
The completion of this primary immunisation is carried out according to 
the information for “Children aged < 12 months” (= age at first adminis-
tered vaccination) in Table 7. Two more vaccinations are required against 
tetanus, diphtheria, pertussis, poliomyelitis and hepatitis B, separated by 
an interval of at least 6 months. One additional dose of a Hib-containing 
vaccine would be sufficient for protection against Haemophilus influen-
za type b, as only 1 dose is needed after the age of 12 months. However, 
both vaccinations can be carried out with a hexavalent vaccine to keep 
the number of injections to a minimum. The additional dose of Hib is 
not likely to pose an increased risk of side effects.
The missing vaccinations against MMR, varicella, and meningococcal C 
have to be administered according to the information for “Children aged 
from 12 months to < 5 years” (because at this time the child is unvacci-
nated against these diseases). The primary immunisation against pneu-
mococci will not be initiated because this vaccination is not recommen-
ded after the age of 24 months (except for children with certain underly-
ing diseases, in which case 2 additional doses would be required at an 
interval of at least 8 weeks). 
Example
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Procedure in the case of missing immunisation  
documentation
If the vaccination card is not traceable or lost, medical files 
should be used to identify previously administered vacci-
nations. Where appropriate, a new vaccination card can be 
issued based on the documented history of vaccinations.
Missing vaccination cards is a frequent problem in dai-
ly life among migrant children, adolescents, and adults. A 
summary of up to date vaccination recommendations ac-
cording to country of origin can be found on the webpa-
ges of the WHO (http://apps.who.int/immunization_mo-
nitoring/globalsummary/schedules) and ECDC (http://
vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx) 
listing all national immunisation plans. In principle, howe-
ver, according to STIKO recommendations, all vaccinations 
that are not documented should be administered under the 
assumption that they are missing.
In case of an unknown vaccination status, including 
missing or incomplete documentation of vaccinations, it 
should be assumed in the interest of the individual to be 
protected that the respective vaccinations are missing. Ana-
mnestic information on vaccination or disease history (in-
cluding measles, mumps and rubella) is, with the exception 
of varicella, often unreliable and should not be incorpora-
ted into the planning of catch-up vaccinations. Deviations 
from this principle might be justifiable in individual cases.
Anamnestic information regarding varicella
Varicella (chicken pox) is an exception regarding the re-
liability of anamnestic information. Studies show that 
such information showing a previous history of varicella 
with typical clinical manifestations is of high validity.3 A 
varicella vaccination is not required after an anamnestic 
response indicating prior varicella disease. If in doubt, a 
varicella vaccination should be administered, especially 
because varicella complications (including pneumonia, 
encephalitis, and the risk of fetopathy if contracted du-
ring pregnancy) increase among adolescents and young 
adults.4 It should be noted that adolescents and young 
adults coming from tropical countries, especially Sou-
theast Asia, are less frequently immune to varicella than 
individuals in Europe.
Indication for serological testing
Serological testing to determine the need for catch-up 
vaccinations based on antibody titres only makes sense in 
exceptional cases, because the test methods used in clini-
cal laboratories often do not have a sufficient sensitivity 
and specificity. For some vaccine-preventable diseases 
(e. g., pertussis), no reliable serological correlate exists that 
would be suitable as a surrogate marker for the presence 
of immunity. Moreover, antibody titre levels do not allow 
drawing conclusions regarding potential cellular immu-
nity. In principle, routine antibody testing is not approp-
riate before or after routine vaccinations. Exceptions are 
verifying vaccination success in patients with immuno-
deficiency (see STIKO notes in Epid. Bull. 39/2005), and 
confirming protection against hepatitis B among persons 
with an elevated exposure risk. Serological testing is also 
recommended to confirm protection against varicella 
among women who wish to conceive and who have unc-
lear anamnesis of varicella.
Are “too many” vaccinations dangerous?
In general, there is no elevated risk of side effects resulting 
from excess vaccine doses. To limit necessary injections, it 
is therefore possible to use combination vaccines even if not 
all antigens/vaccine components are needed (see ‘Choice of 
vaccines’, below). On rare occasions, the repeated administ-
ration of inactivated vaccines can cause adverse events such 
as pronounced local reactions including painful swelling 
and reddening of the affected extremity (called the ‘Arthus 
reaction’). The self-limiting reaction most likely occurs after 
very frequent vaccination with tetanus and / or diphtheria 
toxoid. In this case, antibody testing should be conducted 
before the administration of further Td vaccines. This risk 
does not exist for pertussis antigen.5
For primary immunisation against Haemophilus influenzae 
type b, a single vaccine dose is sufficient after the age of 12 
months. However, the common pentavalent or hexavalent 
vaccines DTaP-IPV-HiB[-HepB] can be used if practical for 
completing the remaining vaccinations. Negative conse-
quences from the surplus Hib component in the vaccine 
are not expected.
Choice of vaccines
Combination vaccines are to be preferred over monovalent 
vaccines if in consequence the number of injections can be 
reduced, the vaccination goal can be reached at an earlier 
date, and vaccination acceptance can be increased. There 
are at present no monovalent vaccines in Germany availab-
le against certain diseases (childhood diphtheria, measles, 
mumps, rubella, and pertussis); in these cases it is inevi-
table to administer combination vaccines (for example, for 
catch-up of a missing mumps or rubella vaccination with 
an MMR vaccine). Individual immunisation schedules are 
often necessary owing to age-dependent changes of vacci-
nation indications (for example, vaccination for Haemophi-
lus influenzae type b until the 5th birthday, and pneumo-
cocci until the 2nd birthday) and the restriction of licensed 
vaccine administration to certain age groups.
The hexavalent vaccine Infanrix hexa® (DTaP-IPV-HiB-
HepB) and the pentavalent vaccine Infanrix®-IPV+Hib 
(DTaP-IPV-Hib) can be given until the age of 36 months 
(the 3rd birthday) according to the Summary of Product 
Characteristics. The hexavalent vaccine Hexyon® (DTaP-
IPV-Hib-HepB) is licensed for use until the age of 24 
months (the 2nd birthday). Following the specifications of 
the Summary of Product Characteristics, the pentavalent 
vaccine Pentavac® (DTaP-IPV-Hib) should not be used in 
children from the age of 6 years. Alternatively, missing vac-
cinations can be completed with the tetravalent vaccine In-
fanrix® (DTaP, licensed until the 6th birthday) and, simul-
taneously or sequentially, with monovalent vaccines against 
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hepatitis B and poliomyelitis. A vaccination series started 
with a specific combination vaccine can be completed using 
vaccines from a different manufacturer.
Depending on age, differently dosed vaccines are used 
for hepatitis B vaccination (for more details see the Sum-
mary of Product Characteristics).
Vaccinations against tetanus, diphtheria, poliomyelitis and 
pertussis from the age of 5 – 6 years
Starting with the age of 5 – 6 years, vaccines with reduced 
antigen content (d instead of D and ap instead of aP) should 
be used for vaccinations against diphtheria and pertussis. 
The corresponding combination vaccines with reduced 
diphtheria and pertussis antigen content (Tdap, Td-IPV, 
and Tdap-IPV) are primarily intended for booster vaccina-
tions. The licensure is based on evidence of efficacy and 
safety for the indication “booster vaccination”.
Td vaccines and monovalent polio vaccines (IPV) are 
licensed for the vaccination of previously unvaccinated in-
dividuals. Because the Td and Tdap vaccines and the respec-
tive Td-IPV and Tdap-IPV vaccines from the same manu-
facturer are identical regarding antigen content of tetanus, 
diphtheria, and polio, it seems immunologically plausible 
that Tdap and Tdap-IPV vaccines are also suitable for this 
group of persons.
Several national immunisation technical advisory groups 
(from Switzerland, France, the United States, and Cana-
da)2,8-10 as well as various experts11-13 recommend without 
restrictions the use of Tdap and Tdap-IPV combination 
vaccines for primary immunisation in this age group.
Currently, data on the use of Tdap and Tdap-IPV vaccines in 
previously unvaccinated persons in this age group are only 
available for a few vaccine products (see footnote below ). It 
is assumed that this application is covered by the licensure. 
However, because it cannot be completely excluded that the 
use of ap-containing vaccines is legally considered an “off-
label use”, STIKO recommends informing the patient and 
documenting this information as a precaution.
Protection against pertussis can currently be achieved 
with a single dose of a combination vaccine including 
the pertussis component in older children and adults, be-
cause these vaccinees are generally not immunologically 
naïve against pertussis given the current prevalence of 
Bordetella pertussis. A study showed that one vaccination 
dose induced an immunological response in more than 
90 percent of vaccinated individuals aged 11 years and 
older.14 Equivalent information can also be found in the 
Summary of Product Characteristics for the respective 
vaccines.
“Off-label use”
Off-label use denotes the prescription of a licensed drug 
product outside of the use for which licensure had been ap-
plied and approved by national regulatory authorities and 
the European Medicine Agency (EMA), including differen-
ces in scope of application (indication), dosage, or duration 
of treatment. In case of off-label use, the physician is liable 
for the medical appropriateness of the treatment as well as 
for potential adverse events. Medical associations recom-
mend that off-label use should only be conducted based on 
valid guidelines and recommendations or acknowledged 
scientific literature. For off-label use, it is indispensable to 
comprehensively inform the patient or legal guardian of 
risks and benefits of the respective vaccination, and that the 
vaccine is being used off-label. Medical treatment and in-
formation have to be documented comprehensively in the 
patient’s file.15-18
Age-dependent recommendations for conducting catch-up 
vaccinations
Age < 12 months
Missing DTaP-IPV-HepB-Hib and pneumococcal conjugate 
vaccine doses should be administered. Three vaccine doses 
should be given with intermediary intervals of 1 month, and 
a 4th dose ≥ 6 months after the 3rd dose to complete a pri-
mary immunisation series. 
There is only a short time slot for catch-up of the rotavi-
rus immunisation series, because administration of the 1st 
dose should take place before the age of 12 weeks and the 
last dose preferably before the ages of 16 weeks (Rotarix®) 
or 20 – 22 weeks (RotaTeq®) depending to the used vaccine 
brand (see Summary of Product Characteristics). The vac-
cination series must be completed by the age of 24 and 32 
weeks, respectively. Additional vaccinations are carried out 
according to the general STIKO immunisation plan.
1  This currently only applies to Boosterix® and Boosterix Polio® (as of July 2013). 
A randomized study examined the immunogenicity and tolerance of Boosterix® (Tdap) and Boosterix Polio® (Tdap-IPV) in comparison to Td vaccine among adults of > 40 years 
of age that had not received a diphtheria or tetanus toxoid-containing vaccine in the previous 20 years.6 Irrespectively of the type of vaccine used, 99 – 100 % of the subjects de-
veloped protecting antibody titres against diphtheria after 3 doses (0–1–6 months). One hundred percent developed protecting antibody titres against tetanus after just 2 vaccine 
doses. These findings also applied to subjects who stated that they had never been vaccinated against tetanus or diphtheria and/or who had no detectable antibody titres at the 
beginning of the vaccination series. Just 1 dose of Tdap or Tdap-IPV induced an immune response against pertussis in 95 % of subjects, without a significant increase after further 
vaccine doses. All vaccines showed comparably good tolerance profiles.6 A similar study also showed comparable immunogenicity and tolerance among adolescents and adults 
aged 15 – 93 years that only received 1 dose of the abovementioned vaccines.7
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Age 12 months to < 5 years
Missing DTaP-IPV-HepB-Hib vaccine doses should be admi-
nistered. To complete a primary immunisation series, 2 do-
ses should be administered with intermediary intervals of at 
least 1 month followed by a 3rd dose ≥ 6 months after the pre-
vious dose. Booster vaccinations are given at the age of 5 – 6 
years (at earliest 2 years after the 3rd dose) and at the age of 
9 – 17 years. From the age of 12 months, Hib only requires 1 
vaccine dose, and pneumococci only 2 vaccine doses at an in-
terval of 8 weeks. From the age of 2 years, pneumococcal vac-
cination is only recommended for children with an increased 
health risk (see specific indication vaccination). In addition, 
2 MMR and varicella vaccinations must be given separated by 
an interval of 4 – 6 weeks, and 1 conjugate vaccination against 
meningococcal C.
Age 5 to < 11 years
Missing polio vaccinations and DTaP or Tdap vaccine do-
ses should be administered using vaccines with an antigen 
content appropriate for age. Until the 6th birthday, accor-
ding to the Summary of Product Characteristics it is possi-
ble to administer the tetravalent vaccine Infanrix® (DTaP) 
and simultaneously inject an IPV vaccination against polio 
(requiring 2 or 3 doses depending on the manufacturer; see 
Summary of Product Characteristics) into the other arm.
From the age of 5 or 6 years (depending on the Summary 
of Product Characteristics), a vaccine with a reduced con-
centration of diphtheria toxoid (d) and pertussis antigen (p) 
should be given. If applicable, the combination vaccines 
Tdap or Tdap-IPV can be used* (3 doses at intervals 0–1–6 
months; see p. 357). Depending on age upon completion of 
the primary immunisation series, it might be appropriate 
for this age group to receive 1 or 2 Tdap booster vaccinations 
between the ages of 10 and 17 years. A booster vaccination 
should be given at the earliest 5 years after the last dose of 
the primary immunisation or the previous booster vaccina-
tion. Primary immunisation against hepatitis B consists of 
3 vaccinations (0–1–6 months). In addition, 2 MMR and va-
ricella vaccinations are given at an interval of 4 to 6 weeks 
and one conjugate vaccination against meningococcal C.
Girls at the age of 9 to 13 and 14 years, respectively (product-
dependent), should receive two HPV vaccinations following 
the immunisation scheme reported in the Summary of Pro-
duct Characteristics.
Age 11 to < 18 years
In case of a missing vaccination against pertussis, protec-
tion can be achieved with 1 dose of a Tdap or Tdap-IPV 
vaccine.14 If primary immunisation against tetanus, diph-
theria and poliomyelitis is also indicated, the first of the 
required 3 vaccinations (0–1–6 months) should be conduc-
ted with a Tdap or Tdap-IPV vaccine* (see p. 357). 
A booster vaccination with Tdap or Tdap-IPV should be 
administered 5 to 10 years after completion of the primary 
immunisation series and if possible before reaching adult-
hood. Primary immunisation against hepatitis B should 
be conducted with 3 vaccine doses (0–1–6 months) using 
the vaccine licensed for the respective age. In addition, 
2  MMR and varicella vaccinations are to be given at an 
interval of 4 to 6 weeks, and one conjugate vaccination 
against meningococcal C. 
Girls under the ages of 13 or 14 years (product-dependent) 
should receive a 2-dose HPV vaccination according to the 
vaccination scheme described in the Summary of Product 
Characteristics. Catch-up vaccinations should be offered 
to older girls and young women until the age of 17 years. 
For catch-up vaccinations at the age of > 13 and > 14 years, 
respectively, 3 doses are necessary (note the Summary of 
Product Characteristics).
Catch-up vaccinations in adulthood
Adults should receive all vaccinations recommended for 
their respective age group, including catch-up vaccinations 
for tetanus, diphtheria, pertussis and poliomyelitis if neces-
sary. Unvaccinated persons or persons with unknown vacci-
nation status can receive 3 doses of a Td or Td-IPV combina-
tion vaccine* (0–1–6 months). To achieve a protection against 
pertussis, the first vaccination should be given as a Tdap or 
Tdap-IPV combination vaccine* (see p. 357).9 Td booster vac-
cinations should be administered in all cases 10 years after 
the previous vaccination. For the first booster, a Tdap combi-
nation vaccine should be used once.
Persons born after 1970 of ≥ 18 years of age should receive 
a one-time measles-virus containing vaccine, preferably an 
MMR vaccine. Women of childbearing age should be given 
2 rubella vaccinations with an MMR vaccine. Varicella vac-
cination (2 doses at an interval of 4 – 6 weeks) is recom-
mended for seronegative women planning pregnancy.
From the age of 60 years, STIKO recommends a one-time 
vaccination against pneumococci and yearly vaccination 
against seasonal influenza as routine vaccinations.
See p. 359 for references and Table 8 regarding the section “Recommenda-
tions for catch-up vaccinations”.
24 of August 2015  Epidemiologisches Bulletin Nr. 34 Robert Koch-Institut 359
Antigen Brand name Minimum age a Maximum age a 
DTaP Infanrix® 2 months 6th birthday (72 months)
DTaP-IPV-Hib Infanrix-IPV + Hib® 2 months 3rd birthday (36 months)
Pentavac® 2 months 6th birthday (72 months)c
DTaP-IPV-HepB-Hib Infanrix hexa® 2 months 3rd birthday (36 months)
Hexyon® 6 weeks 2nd birthday (24 months)
Td Td-Immun®, Td-Impfstoff ®, Td-pur® 5th birthday (60 months) no age limit
Td-Rix® 6th birthday (72 months) no age limit
Tdap Boostrix®, Covaxis®, TdaP-IMMUN® 4th birthday (48 months) no age limit
Tdap-IPV Boostrix Polio® 4th birthday (48 months) no age limit
Repevax® 3rd birthday (36 months) no age limit
Td-IPV Revaxis® 5th birthday (60 months) no age limit
IPV IPV-Mérieux® 2 months no age limit
MMR M-M-RVaxPro® (9 –) 12 months b no age limit
Priorix® 9 months no age limit
MMR-V Priorix-Tetra® (9 –) 11 months b 13th birthday
Varicella Varivax® (9 –) 12 months no age limit
Varilrix® (9 –) 11 months no age limit
Table 8: Brand names and indicated age groups of vaccines available in Germany mentioned in the text 
             (list does not claim to be exhaustive)
a See also Summary of Product Characteristics (as of July 2015).
b If immunisation protection is considered necessary at an earlier point in time, vaccination can be given starting at the age of 9 months; see 
      recommendations for measles, mumps, and rubella (p.338). 
c Limitation by age not mentioned explicitly anymore in the Summary of Product Characteristics as of July 2015.
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Notice
Disclaimer
This document is a translation of the original Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute 
(http://www.rki.de/stiko-empfehlungen) on behalf of the Robert Koch Institute as of 8/2015. The German text is authoritative, and no liability is assu-
med for any translation errors or for the translation’s correctness in case of subsequent revisions to the German original.
National immunisation plan available in 15 languages: www.stiko.de/en
